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Abstract
Protozoan parasites from the genus Leishmania cause broad clinical manifestations
known as leishmaniasis, which affect millions of people worldwide. Cutaneous leishmaniasis
(CL) is mainly caused by either Leishmania major or L. tropica parasites, which produce
localized cutaneous ulcers, often leading to scarring and social stigma. Currently, the disease has
reached hyperendemicity levels in the Middle East due to conflict and human displacement and
is one the most common forms of the disease in the Old World. Furthermore, the first choice of
treatment in that region continues to be pentavalent antimonials, which are costly and highly
toxic, and current vector control measures alone are not sufficient to stop disease transmission.
CL remains largely neglected, with no prophylactic or therapeutic vaccine available, and existing
drug treatments are expensive, have toxic side effects, and resistant parasite strains have been
reported. Hence, further therapeutic and preventive interventions against the disease are
necessary.
In this regard, previous studies from our laboratory, reported promising in vitro antileishmanicidal findings of a novel series of organometallic compounds containing RuII and
clotrimazole (CTZ) termed AM160 or AM162 [1]. For the first part of the present study, we
determine the efficacy of AM160 or AM162, in BALB/c infected mice with L. major metacyclic
promastigotes to alleviate CL. AM162 treatment (4 mg/kg/day) reduced the lesion size in the
murine model of CL by a 68%, a markedly better effect than CTZ alone or a RuII complex not
containing CTZ (C3). In addition, in a hyper infection experiment, AM162 treatment at 6
mg/kg/day significantly (p=0.0146) reduced CL footpad lesions and parasite load in comparison
with vehicle control group, with no significant toxicity observed. Moreover, we investigated the
potential mechanism of cell death inflicted by RuII CTZ complexes on L. major promastigotes.
vii

AM160 and AM162 exhibited pro-apoptotic-like properties, implicating phospholipids
externalization, mitochondrial depolarization and DNA fragmentation, as its mechanism to
induce cell death in L. major parasites; encompassing early and late hallmarks of apoptosis.
Overall, these findings indicate that AM162 complex is an efficient compound for the treatment
of CL in a murine model.
Furthermore, the second part of this dissertation focuses on the development of a vaccine
based on terminal, non-reducing, and linear α-galactopyranosyl (α-Gal) epitopes that are
abundantly

found

on

the

plasma

membrane

glycolipids

of L.

major known

as

glycoinositolphospholipids (GIPLs). Previous studies have suggested that sugars are promising
vaccine candidates against leishmaniasis, since most parasite species have a cell surface coat
composed of immunogenic sugars, including linear α-Gal epitopes, which are absent in humans.
Here, we evaluated three neoglycoproteins (NGPs), containing synthetic α-Gal epitopes
covalently attached to bovine serum albumin (BSA), as vaccine candidates against L. major,
using α1,3-galactosyltransferase-knockout (α1,3GalT-KO) mice. These transgenic mice,
similarly to humans, do not express non-reducing, linear α-Gal epitopes in their cells and are,
therefore, capable of producing high levels of anti-α-Gal antibodies. We observed
that Galα(1,6)Galβ-BSA (NGP5B), but not Galα(1,4)Galβ-BSA (NGP12B) or Galα(1,3)GalαBSA (NGP17B), was able to significantly reduce the size of footpad lesions by 96% in
comparison to control groups. Furthermore, we observed a robust humoral and cellular immune
response with production of high levels of protective lytic anti-α-Gal antibodies and induction of
Th1 cytokines. When tested in transgenic mice, which like humans, lack α-Gal epitopes in their
cells, NGP5B was able to induce a significant partial protection against L. major infection by
significantly reducing mouse footpad lesions and parasite burden. Altogether, we propose
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NGP5B as a promising preventive vaccine, and AM162 as a treatment option for CL caused by
L. major.
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Chapter 1: General introduction
1.1

Leishmaniasis
Leishmaniasis is a world-wide vector borne disease transmitted by the bite of an infected

female Phlebotomus or Lutzomia sand fly in Old and New Worlds, respectively. Presently, this
disease is endemic threatening 350 million people worldwide, with a prevalence of 12 million
people, and an annual incidence of 2 million cases [2]. Furthermore, more than 20 species of
Leishmania are pathogenic to humans, causing three major clinical manifestations of the disease:
visceral (VL), mucocutaneous (MCL), or cutaneous leishmaniasis (CL) [3]. VL is the most
severe form of the disease, caused by L. donovani and L. infantum in the Old World and L.
chagasi in the New World. VL is fatal if untreated, causing around 40,000 deaths and 300,000
new cases annually [3]. Symptoms include fever, splenomegaly, hepatomegaly, progressive
anemia, and extreme weight loss [3]. Post kala-azar dermal (PKDL) is presented after months to
years in VL treated patients. This manifestation triggers severe dermatitis, forming small skin
lesions, to large nodules that can further transform into large ulcers or plaques [3]. MCL occurs
in the New World, and it is mainly caused by L. braziliensis and L. panamensis. It affects the
mucosal membranes, developing disfiguring and destructive lesions that usually start appearing
in nasal mucosa, spreading to the pharynx, oral mucosa, and the larynx [3].
CL is the most common form of the disease with an annual estimate of 0.7 to 1.2 million
cases [4]. The disease causes localized or diffused skin ulcers, causing social prejudice due to the
formation of exposed skin lesions. Lesions can self-heal in several months, or undergo slowhealing leading to permanent scaring in patients [5]. Old World CL is mainly transmitted by L.
major or L. tropicana in the Middle East, Southern Europe, Southwest Asia and Africa; and L.
1

mexicana, L. amazonensis, L. brazilenzis in the New World (Central and South America) [3].
Additionally, CL is an emerging concern in the United States, because of travel and migration
within the tropics, subtropics, Middle East and Southern Europe [6]. Approximately, as of 2005
around 0.23% U.S. military troops station in Iraq and Afghanistan were diagnosed with
leishmaniasis (VL or CL) [7]. In addition, increasing numbers of natural transmission CL cases
have been reported in states such as Texas and Oklahoma [8, 9].
The life cycle of Leishmania spp. alternates between promastigotes (lance-like structure)
in insect and amastigotes (round-like structure) in vertebrate hosts [3]. Furthermore, they have a
relatively large nucleus and one single mitochondrion, where mitochondrial DNA is found
locally condensed and named kinetoplast. The transmission of the parasite occurs by the bite of
an infected sand fly to its mammalian host. First, the infected sand fly takes a blood meal
injecting the metacyclic promastigote parasite form into the bloodstream of its host. Then,
macrophages phagocytize the metacyclic promastigotes that reach the puncture wound. Here,
the metacyclic promastigotes transform into non-motile intracellular amastigotes which
proliferate inside macrophages by simple division. The amastigotes replicate until cells burst,
and the released amastigotes are phagocytized by other cells, thus infecting more cells. The cycle
continues when the female sand fly is infected by taking up a blood meal, where ingested
amastigotes change into motile, and flagellated promastigotes colonizing the midgut and/or
hindgut of the vector, and migrating to the proboscis of the sand fly. The infection is
retransmitted during a blood meal to different vertebrate host, restarting the life cycle (modified
from Kaye and Scott, 2011) [10] (Fig 1.1).
Currently, there is no commercially available preventive or therapeutic human vaccine
for any clinical manifestation of leishmaniasis. Thus, when vector control fails, infected patients
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rely on toxic and expensive drugs, that are more ineffective every day due to emerging parasite
resistant strains. Therefore, it is important to emphasize the need of novel possibilities for
the treatment and prevention against cutaneous leishmaniasis.

3

Fig 1.1 Life cycle of Leishmania spp [10].
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1.2

Current treatments for leishmaniasis

Effective treatment against all clinical manifestations of leishmaniasis are mostly based
in pentavalent antimonials [Sb(V)] developed more than 60 years ago such as sodium
stibogluconate (Pentostam) or meglumine antimoniate (Glucantime) (Fig 1.2) [11]. Although
antimonials present several advantages such as low cost and high efficacy for VL (35-90%), and
CL (25-100%) [3], these drugs exhibit side effects such as anorexia, nausea, vomiting, increase
in hepatic enzymes, tachycardia, and severe to fatal arrhythmias [12, 13]. Another disadvantage
is the administration and long treatment periods of antimonials. For instance, administration can
be either by intravenous infusions or intramuscular injections at 20 mg/kg for 20-38 days for VL;
and intralesional treatment with 5 separate doses every 5-7 days, or systemically at 20 mg/kg for
20 days in the case of CL [3, 13]. Furthermore, in Bihar, India around 1980’s, antimonials started
to be ineffective in relapsed patients with VL [14]. Its efficacy decreased by a 65%, mainly
because the widespread misuse of the drug, and the emergence of Leishmania antimonyresistance [3, 13, 14]. Its mechanism of action is not well understood, however, different theories
have been considered. First, Sb(V) is a prodrug, meaning that Sb(V) undergoes biological
reduction to a trivalent form of antimony [Sb(III)] with potent anti-leishmanial activity [11].
Second, Sb(III) induced apoptosis cell death in Leishmania amastigotes by DNA fragmentation,
externalization of phospholipids, oxidative stress, and an increase in intracellular Ca2+ levels
[15]. Sodium stibogluconate, but not Sb(III), specifically inhibits type I DNA topoisomerase in
Leishmania donovani [16]. Additionally, Sb(V) inhibits macromolecular biosynthesis function in
Leishmania mexicana amastigotes, possibly by inhibition of glycolysis and fatty acid oxidation
[17, 18]. The potential targets of Sb(III) is trypanothione reductase (TR). Sb(III) inhibits TR
enzyme, producing an efflux into Leishmania parasites of trypanothione (parasite-specific thiol)
5

which is involved in the reduction of Sb(V) to Sb(III), and glutathione (main thiol present in
mammalian cells) [11].
Amphotericin B deoxycholate is a polyene antibiotic used in systemic fungal infections,
and typically, the second line treatment for leishmaniasis [3]. Nevertheless, it was introduced as
the first line of treatment for VL in places such as Bihar, India, where antimonial-resistance was
observed [19]. The mechanism of action of amphotericin B is through the binding of sterols such
as ergosterol, forming transmembrane channels damaging the parasite membrane, resulting in
cell death [20]. Amphotericin B deoxycholate is mostly used for the treatment of VL, with high
efficacy rates close to 100% [21]. Nonetheless, intravenous diffusions for CL at 0.7 mg/kg per
day, for 25 to 30 doses have been reported [3]. Besides its high efficacy, adverse effects such as
hepatotoxicity, hypokalemia, nephrotoxicity, myocarditis, or even death have been previously
documented, therefore, hospitalization may be necessary for monitoring of patients [21].
Furthermore, lipid formulations such as AmBisome; Gilead Sciences, at 2−3 mg/kg per day, up
to 20−40 mg/kg total dose are also used for treatment of CL. The creation of lipid formulations
(AmBisome) significantly reduced the side effects observed with amphothericin B deoxycholate
treatments [3]. Nonetheless, liposomal amphothericin B is considered the most expensive antileishmanicidal drug today. Even though Gilead Sciences and the World Health Organization
(WHO) agreed to lower the price in endemic regions to $20 per 50 mg vial of AmBisome in
2007, a total dose of 20 mg/kg is needed ($480 for a 60 kg person) [21]. Also, AmBisome in
nonendemic areas is extremely expensive, and hospitalization and closer monitoring of patients
is required [22].
Miltefosine (hexadecylphosphocholine) was first introduced as an anticancer drug,
however, in the 1980’s miltefosine exhibited anti-leishmanicidal activity [23]. Currently, it is the
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only effective oral treatment against CL [3]. More importantly, in 2014, the Food and Drug
Administration (FDA) approved miltefosine or IMPAVIDO (Paladin Therapeutics, Canada) for
the treatment of CL (L. braziliensis, L. guyanensis, and L. panamensis), VL (L. donovani) and
MCL (L. braziliensis) in the United States (FDA approved package). According to the FDA, the
treatment is administrated for 28 consecutive days, taking 50 mg capsule two to three times a
day. Even tough, an oral treatment is ideal for diseases such as leishmaniasis, IMPAVIDO
presents several limitations for its use; such as embryo-fetal toxicity, fetal death, and a long halflife (150 hours), which may facilitate the emergence of drug resistance [3]. Also, the efficacy
of IMPAVIDO differs between Leishmania species, for instance, CL caused by L. panamensis
showed 70 to 90% cure rate, on the other hand, CL caused by L. mexicana less than 60% [3].
The mode of action of miltefosine against Leishmania species is unknown and not well studied,
however, cell death by apoptosis in L. major, L. tropicana, and L. donovani species was
previously observed [24, 25].

7

Fig 1.2 Chemical structures of current therapies against leishmaniasis. Meglumine
antimoniate, sodium stibogluconate, miltefosine, and amphothericin B.
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Azoles and Metal-based Therapies for Leishmaniasis
Trypanosomatids required the synthesis of ergosterol and other 24-alkyl sterols, for their
proper function and structure [26, 27]. Accordingly, sterol biosynthesis inhibitors (SBI), are
known to block the proliferation of the parasite by inhibiting the cytochrome P-450 dependent c14α-demethylation of lanosterol to ergosterol, triggering accumulation of 14α- methyl sterols
[27]. Azoles are ergosterol biosynthesis inhibitors previously validated as potential antileishmanicidal drugs [27]. For instance, fluconazole in L. major infected patients from Saudi
Arabia, displayed a moderate cure rate of 59% [28], and ketoconazole previously tested in CL
patients caused by L. braziliensis resulted in a 76% cure rate [29]. However, in the case of
itraconazole, it presented low efficacy in L. major infected patients in comparison to placebo
group [30]. Topical treatment with 1% clotrimazole (CTZ) was used in CL patients from Saudi
Arabia, and from a total of 89 lesions treated with clotrimazole, only 14 were completely cured,
and 42 lesions were reduced in size [31].
The development of metal-based complexes as chemotherapy agents against
trypanosomatids has been recognized as a promising approach, by increasing the activity of the
parental drug and decreasing the toxicity against mammalian cells [32, 33]. The rationale behind
this approach, is a metal-ligand synergism, to simultaneously modulate multiple targets. For
instance, the transition metal Ruthenium (Ru), displayed several biological properties, such as
low toxicity to humans, DNA binding, and the ability to mimic iron binding to biomolecules
such as albumin and transferrin, and ligand exchange kinetics similar to those of platinum
antitumor drugs[1, 34]. Furthermore, recent reports demonstrated the potential use of Ru-based
complexes against parasitic diseases such as Chagas disease and leishmaniasis [34,35]. In this
regard, first generation of Ru-CTZ compounds studied by the Sanchez-Delgado group [36]

9

displayed encouraging in vitro results towards Trypanosoma cruzi epimastigotes, achieving 90%
inhibition at concentrations of 10-5 M. In addition, eradication of infected Vero cells with the
intracellular form of the parasite was achieved at concentrations of 10-8 M, with a better effect
that CTZ alone, and less cytotoxicity [36]. Therefore, a first generation Ru-CTZ compound
termed [Ru2(CTZ)2] (Fig 1.3) was found to increase their activity by a synergistic effect due to
the presence of a metal, and its SBI function [36]. However, poor water solubility limited the
availability to test in an in vivo model [36]. Subsequently, evaluation of a second generation of
Ru-CTZ (AM160 and AM162) (Fig 1.3) complexes synthetized by the Sanchez-Delgado group,
displayed high antiparasitic activity with 110 and 58 times more active than CTZ alone in T.
cruzi and L. major respectively, and excellent therapeutic index [1]. Altogether, the metal-azole
complexes are potential chemotherapeutic agents against leishmaniasis [1, 37].

10

First Generation of Ru-CTZ
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Fig 1.3 Chemical structures of clotrimazole (CTZ) parental drug, first generation of RuCTZ [RuCl2(CTZ)2], and second generation AM160 and AM162. Ru, ruthenium; CTZ,
clotrimazole .
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1.3

Experimental vaccines against leishmaniasis
Several experimental approaches have been studied for the development of an effective

vaccine against Leishmania spp. [38, 39]. First attempts at vaccination, showed 100% efficacy in
places such as the Middle East, Israel, Central Asia and Soviet Union using an ancient approach
called “leishmanization” [40, 41]. Initially, individuals were inoculated in unexposed body parts
with live L. major parasites, to produce CL infection. However, the procedure was abandoned
due to safety regulations, persistent of CL lesions, and immunosuppression in individuals [40].
As an alternative, first generation vaccines based on whole-cell-killed (autoclaved) Leishmania
major promastigotes either alone or in combination with bacillus Calmette-Guérin (BCG) as
adjuvant were studied [42, 43]. However, difficult standardization, poor protection, and
variations between trials were observed [44].
Second generation vaccines use alternative methods such as genetically modified
parasites lacking essential genes, recombinant proteins, DNA vaccines, or specific antigen-based
vaccines [38]. Several vaccine antigens have been considered, such as recombinant Leishmania
homologue for receptors of activated C kinase (LACK) in combination with IL-12 against L.
major protection [44], surface expressed glycoprotein leishmaniolysin (gp63) [45], hydrophilic
acylated surface proteins (HASP) [46], and Leishmania-derived recombinant poly-protein
(LEISH-F1) formerly known as Leish-111f, which was able to protect mice [47, 48].
LEISH-F1 is a vaccine candidate developed at The Infectious Disease Research Institute
(IDRI, Seattle, WA). A polyprotein recombinant Leishmania vaccine containing three proteins
derived from L. major, and conserved between different Leishmania spp. It is composed of the
following proteins: Leishmania elongation initiation factor, thiol-specific antioxidant, and L.
major stress-inducible protein 1, in formulation with the monophosphoryl lipid A-stable
12

emulsion (MPL-SE). LEISH-F1 is the first second generation vaccine candidate to enter phase I
clinical trials in United States, Colombia, Brazil, India, and Peru, demonstrated the safety and
immunogenicity of healthy individuals [49]. Likewise, LEISH-F1 moved to phase II clinical
trials as a therapeutic vaccine in combination with meglumine antimoniate (Glucantime)
treatment, in CL infected subjects in Brazil. A total of 80% of vaccinated individuals were
clinically cured by day 84, in comparison with only 38% of the placebo group [50]. Considering
the encouraging results observed with LEISH-F1 [47, 48, 50, 51], the IDRI follow the same
concept and generated LEISH-F2 and LEISH-F3. LEISH-F2+MPL-SE confirmed to be safe and
immunogenic in phase I clinical trial, and effective in CL infected adults and adolescents in
phase II when compared to the standard drug sodium stibogluconate, as a therapeutic vaccine
(https://clinicaltrials.gov/ct2/show/NCT01011309) [53]. Furthermore, LEISH-F3 is composed of
two proteins conserved between Leishmania spp. The 35 kDa glycoprotein, nucleoside hydrolase
(NH), which is a main component of the highly immunogenic fucose-mannose ligand complex of
L. donovani; and 45 kDa enzyme 24-c-methyltransferase (SMT) of L. infantum, a series of amino
acids that are is absent in mammals [52]. Phase I trials with LEISH-F3+GLA-SE, proved to be
immunogenic and safe, with predominant Th1 immune response by the activation of CD4+ T
cells secreting IL-12, IFNγ, and TNF cytokines, in healthy adult volunteers from non-endemic
areas in Washington, USA [52].
Furthermore, previous reports have shown that the sand fly saliva plays a critical role in
the establishment and maintenance of Leishmania spp. in the mammalian host, as well as in the
pathogenesis of leishmaniasis and immune responses against the parasite (reviewed in [53, 54]).
Oliveira et al. [55] demonstrated the protective effect of Phlebotomus duboscqi uninfected sand
fly bites in rhesus macaques. First, they observed that only 30% of animals exposed to
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uninfected sand fly bites followed by vector-transmitted L. major challenge, exhibited ulcerated
lesions, in comparison to 70% of naïve animals. Furthermore, macaques immunized with a P.
duboscqi-derived recombinant salivary protein (PdSP15), followed by sand fly-challenge with L.
major, showed a significant reduction in disease burden, by decreasing CL lesions and parasite
load, resulting from an early Th1-mediated anti-parasitic protective immune response involving
CD4+IFN-γ+ T cells.

L. major glycoinositolphospholipids (GIPLs) and glycovaccines

Recently, carbohydrates have been proposed as potential targets for vaccines against
Leishmania spp. [56, 57]. For instance, vaccination with purified lipophosphoglycan (LPG) from
L. donovani failed to protect against L. major infection in BALB/c mice [58]. Conversely,
Pinheiro et al. [59] demonstrated that intranasal vaccination with L. amazonensis LPG provided
protection in BALB/c mice against subsequent parasite challenge. Additionally, a synthetic
glycovaccine

containing

fragments

of

the

phosphoglycan

moiety

of

LPG

or

proteophosphoglycan (PPG) from L. mexicana exerted a protective effect in a natural sand fly
infection model of CL caused by L. mexicana [60]. Nonetheless, full protection was not
accomplished in these studies.
Evasion mechanisms such as the formation of a protective barrier known as glycocalyx,
helps in the proliferation and parasite survival, inside the hostile environment of macrophages
[61]. The parasite’s glycocalyx is composed of a complex coat of glycoconjugates including
LPG, PPG and protein-free glycoinositolphospholipids (GIPLs) [62-66]. GIPLs are composed of
a conserved core structure Manα1,4GlcNα1,6myo-inositol-1-PO4-, attached through the myoinositol-linked phosphate residue to a hydrophobic moiety containing an alkylacylglycerol [62].
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Based on its glycan composition, three different types of GIPLs have been described in L. major
(Fig 1.4) [62, 67]. The three main types of GIPLs have a rich mannose or/and galactosecontaining glycan moiety (Fig 1.4). Interestingly, type-II GIPLs in L. major contain terminal,
non-reducing α-Galactopyranosyl

(α-Galp or α-Gal) residues

at different structural

configurations [68]. Furthermore, Type-II GIPLs are highly abundant at the surface of L. major,
and conserved through the parasite’s life cycle [65]. Due to the inactivation of the α1,3galactosyltransferase (α1,3GalT) gene [69], terminal, non-reducing and linear α-Gal epitopes are
absent and, therefore, highly immunogenic to humans and Old World nonhuman primates. More
recently, Jaurigue and Seeberger [57] have proposed α-Gal epitopes as vaccine candidates
against Leishmania spp. Therefore, terminal, non-reducing α-Gal residues found in type-II
GIPLs in L. major are attractive targets for the development of a protective vaccine against CL.
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Fig 1.4 Different types of protein-free glycoinositolphospholipids (GIPLs) in L. major [41].
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1.4

Hypothesis & specific aims

Hypothesis:
Based on evidence on the literature on Ruthenium-CTZ complexes behavior and previous results
in our laboratory, we hypothesized that the Ru-CTZ complexes will have a potent leishmanicidal
effect in the murine model for CL, in comparison with CTZ alone. We speculate that Ru is
acting as a carrier to help the azole across the parasite’s membrane. Once the Ru-Azole complex
is inside the parasite, it is hydrolyzed, releasing the Ru. At this point the azole will produce its
action as sterol biosynthesis inhibitor and the Ru will induce an apoptotic-like mechanism,
subsequently killing the parasite.
Specific aim 1: Chemotherapeutic approach: Ruthenium-Clotrimazole complex has significant
efficacy in the murine model of cutaneous leishmaniasis.

Hypothesis:
Due to the highly immunogenicity of terminal non-reducing α-Gal residues found in type-II
GIPLs in L. major, we propose that a synthetic α-Gal-containing neoglycoprotein-based vaccine
will protect against the L. major infection in an α1,3-galactosyl transferase-knockout (α1,3GalTKO) mouse model.
Specific aim 2: Immunological approach: An α-Gal-containing neoglycoprotein-based vaccine
partially protects against murine cutaneous leishmaniasis caused by Leishmania major.
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Chapter 2: Ruthenium-clotrimazole complex has significant efficacy in the
murine model of cutaneous leishmaniasis ∗
2.1

Introduction
Trypanosomatid protozoa of the genus Leishmania are the causative agents of

leishmaniasis. This parasitic disease, which targets mainly macrophages, is transmitted by the
bite of an infected female phlebotomine sand fly. Currently, this disease is endemic in 98
countries, with more than 2 million new cases per year, and high levels of mortality and
morbidity [4]. More than 20 species of Leishmania affect humans, causing three major different
forms of the disease. Cutaneous leishmaniasis (CL), caused by Leishmania major (L. major), is
the most common form of the disease with an estimate of 0.7 to 1.2 million annual cases,
characterized by localized cutaneous ulcers [5, 70]. Even though CL is considered to be a
tropical disease, increased travel and migration within the tropics, subtropics, Middle East and
Southern Europe are making this disease a risk for population in regions that were previously
unaffected, including the United States, where it is an emerging concern [6].
Efforts to discover a reliable human anti-Leishmania vaccine remain elusive, and current
anti-Leishmania chemotherapy is mostly based in pentavalent antimonials developed over 50
years ago and liposomal amphotericin B (amp B) [12]. Pentavalent antimonials remain effective
and they are the preferred treatment for CL [71]. In addition to their highly toxic side effects,
antimonials resistance in Leishmania spp. has been reported, restricting limits of their usage [72]
∗ Note: This chapter is the basis for the manuscript 2 (see list of publications and manuscripts): E. Iniguez, A. Varela-Ramirez, A. Martínez, C.
L. Torres, R. A. Sánchez-Delgado, and R. A. Maldonado (2016). Ruthenium-Clotrimazole complex has significant efficacy in the murine model
of cutaneous leishmaniasis. Acta Tropica. 164:402-410. DOI: 10.1016/j.actatropica.2016.09.029
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[12]. In regions where leishmanial resistance to antimonial is high, amp B deoxycholate is
recommended [21]; nevertheless, its usage has several drawbacks, such as high toxicity with its
concomitant low tolerance by patients, especially when long periods of treatment are needed
[22]. In contrast, due that liposomal amp B is a better-tolerated drug and is widely available in
the U.S. (at a dosage of 3 mg/kg, days 1–5, 10 and 21) for CL treatment, the usage of amp B
deoxycholate for the treatment of leishmaniasis was already eradicated [22]. However, liposomal
amp B is expensive and to be effective requires a long course of high dose treatment. For
instance, a total 21 mg/kg dose drug cost for a 70-kg patient is between $5,000.00-6,000.00, in
agreement with FDA-approved guidelines for visceral leishmaniasis (VL); an additional
disadvantage is that this drug is not FDA-approved for CL treatment and some health insurance
companies will hesitate to cover its cost for CL treatment purposes [22]. Additionally,
miltefosine is the only effective oral agent for leishmaniasis management (FDA approved).
Nonetheless, it is also expensive and can produce several side effects [73]. Thus, there is an
urgent need for the development of new chemotherapies against leishmaniasis.
In previous studies we reported a novel series of organometallic compounds containing
RuII and clotrimazole (CTZ) displaying potent leishmanicidal activity without significant toxicity
toward normal mammalian cells, most notably AM160, and AM162 [1, 37]. As complex metal
compounds, both AM160 and AM162 increased the toxic activity of CTZ on L. major
promastigotes (after 96 h exposure), most likely due to their ruthenium (RuII)-containing motifs,
as evidenced by an LD50 of 0.015 and 0.45 µM, respectively [1, 37]. In addition, the effects of
both AM160 and AM162 on intracellular proliferation of L. major amastigotes in mouse
intraperitoneal macrophages was studied after 48 h of treatment by using high-content imaging
assay [74]. Findings indicate that AM160 caused significant inhibition on the proliferation of
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intracellular amastigotes (IC70= 29 nM), while AM162 displayed anti-leishmanicidal effect at a
higher concentration (IC40= 1 μM) [1, 37]. CTZ is known to act as an sterol biosynthesis
inhibitor (SBI), blocking the proliferation of the parasite by inhibiting the action of the enzyme
C-14 demethylase, and it has been shown that ruthenium markedly enhances their activity
towards L. major with undetectable cytotoxic effects towards mammalian cells through a
synergistic mechanism [75]. Due to these promising in vitro findings, in the present study, we
sought to determine the efficacy of the Ru-CTZ compounds specifically AM160 and AM162 in
BALB/c mice infected with L. major metacyclic promastigotes to alleviate CL. Moreover,
among various mechanisms of cell death, apoptosis or programed cell death has been reported in
several parasitic protozoans [25, 76-78]. Therefore, we investigated the mechanism of cell death
inflicted by RuII-CTZ complexes on L. major promastigotes.
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2.2

Materials and methods

Parasite culture and maintenance
Promastigote forms of L. major strain Friedlin clone V1 expressing luciferase gene [79] were
grown in 1X M199 medium supplemented with hemin and 10% heat inactivated fetal bovine
serum (FBS). For the in vivo infections, L. major metacyclic promastigotes were prepared by
Ficoll-Paque density gradient centrifugation as previously described [80].

Synthesis of Ru-azole complexes
Ru-azole complexes [(p-cymene)RuCl2(CTZ)] (AM160), and [(p-cymene)RuCl(acac)(CTZ)]BF4
(acac = acetylacetonate) (AM162), the metal-ligand motif (C3) and CTZ were synthesized and
purified by appropriate chemical methods as previously described [1, 37]. The Ru-azole
compounds were freshly dissolved at the stated concentrations in 50 % v/v DMSO/PBS solution
and daily administered intraperitoneally for 14 or 10 consecutive days for the pilot or hyper
infection experiments, respectively for the in vivo studies. For mechanistic in vitro studies,
compounds AM160, AM162 were dissolved in DMSO.

Pilot and hyper infection in a murine model
Female BALB/c mice (6-8 weeks old) were acquired from Harlan Laboratory (Indianapolis, IN).
Only female mice were utilized for a series of experiments in vivo to circumvent gender
associated influences [81]. For the pilot and hyper infection, 1x105 or 1x106 L. major metacyclic
promastigotes in 50 µl volume, respectively, were inoculated into the left hind footpad. Mice
were individually treated with AM160 or AM162 at 4 mg/kg/day for the pilot or 6 mg/kg/day for
the hyper infection, and monitored for 14 or 21 dpi, respectively. Disease progression was
examined twice per week by checking body weight and swelling of the Leishmania cutaneous
lesion (left footpad) with a digital caliper. During the hyper infection experiments, as soon as the
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CL lesions were visually evident at day 21 post-infection, animals were randomly selected to
conform both experimental and control groups without any bias; followed by the measurements
of the lesion size. Due to the high variability of CL lesion sizes between the animal groups, the
lesion sizes were normalized as 1 per each group at 21 dpi, for comparison purposes with day 34
post-infection (endpoint of experiment). Mice treated with vehicle (50% v/v DMSO/PBS
solution) were considered as negative control; naive group, non-infected mice with L. major
metacyclic promastigote, but just AM162-treated animals were concurrently analyzed.
Furthermore, mice treated with the metal-ligand motif (C3) not containing CTZ, as well as CTZ
alone, at a concentration of 4 mg/kg/day, were also included as controls. Animal procedures
were performed according to NIH guidelines and the appropriate protocol approved by UTEP's
Institutional Animal Care and Use Committee (IACUC).

Determination of parasite load and cycle threshold using quantitative RT-PCR
Genomic DNA was obtained from BALB/c mice footpads by chloroform-phenol extraction as
previously described [82]. First, footpad tissue was obtained and dissociated with gentle MACS
dissociator (Miltenyl Biotec), centrifuged for 10 min at 3000 rpm, and resuspended with 150 μl
of TELT buffer. The same volume 1:1 of chloroform-phenol was added and phases were
separated by centrifugation. The aqueous phase was recovered, and the DNA was precipitated
with ethanol followed by centrifugation. The DNA pellet was washed with 70% ethanol, and
resuspended in 50 μl of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) with 20 μg/ml of
RNase A. Parasite load was determined by the cycle threshold value [83] with SYBR Green
(Bio-Rad, Hercules, CA) and used for product detection and quantification of 120-bp fragment
of

the

minicircle

kDNA

of

CCTATTTTACACCAACCCCCAGT-3';

L.

major

primers

and

JW12

(reverse,
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JW11

(forward,

5'-

5'-GGGTAGGGGCGTTC

TGCGAAA-3') [84]. Primers were obtained from Integrated DNA Technologies (IDT)
(Integrated DNA Technologies, Coralville, IA). Amplification and detection was performed
using Step One Real Time PCR System (Life Technologies) as follows: holding step at 95°C for
15 min, 40 cycles starting in denaturation step at 95°C for 15 seconds, annealing at 56°C for 10
seconds and extension step at 72°C for 10 seconds. Reactions were standardized using a 10-fold
serial dilution of promastigotes DNA (50 ng per reaction). Standards, experimental samples and
controls were analyzed in triplicates in two independent biological replicates. The results are
represented by parasite equivalents.

Analysis of apoptosis-like pathway via annexin V/PI assay
To quantify cells with phospholipids externalization, Alexa Fluor® 488 annexin V/PI Apoptosis
Kit (Invitrogen™-Life technology, Grand Island, NY) was used and monitored by flow
cytometer. L. major promastigotes (5 x 106) were treated with AM160 or AM162 at 2 μM. After
24 h of exposure, the cells were harvested, washed and resuspended with cold PBS and analyzed
via flow cytometric protocol following the manufacturer's instructions of annexin V/PI kit. As a
positive control, cells treated with 200 μM of hydrogen peroxide (H2O2), and as negative control,
cells treated with diluent only (DMSO) were analyzed concomitantly. The total percentage of
apoptotic cells was obtained with the sum of both early and late apoptotic percentages located in
the two right quadrants of the flow cytometric dot plots. For each sample, 10,000 events were
collected and analyzed by using a Cytomics FC500 flow cytometer and CXP software (Beckman
Coulter, USA).

Analysis of mitochondrial membrane potential (Δψm)
L. major promastigotes (5 x 106) were treated with several concentrations (0.25, 0.50 and 1 μM)
of AM160 or AM162 for 6 h and stained with 2 μM of the fluorophore 5',6,6'-tetrachloro23

1,1',3,3'-tetraethylbenzimidazolylcarboncyanine iodide (JC-1), following a modified version of
manufacturer's instructions (MitoProbe JC-1 Assay Kit, Life technologies, Grand Island, NY).
The disruption of mitochondrial membrane potential produces a shift of the JC-1 fluorescenceemitting signal from red to green. For each sample, cells with JC-1 aggregates or monomers,
emitting red or green signal, were analyzed with Cytomics FC500 flow cytometer by using FL-2
and FL-1 detectors, respectively. Cells treated with the drug diluent (DMSO) were consider as
negative control; whereas cells treated with 50 μM carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) were used as positive control. Data collection and analysis was performed using CXP
software (Beckman Coulter).

Detections of DNA fragments by Terminal deoxynucleotidyl transferase-mediated d-UTP Nick
End Labeling (TUNEL) assay
L. major promastigotes (5 x 106) were treated at a concentration of 2 μM AM160 or AM162 for 6
h. Parasites were harvested and fixed with 4% paraformaldehyde, followed by incubation with
0.2% Triton X-100 in PBS for 5 min at room temperature for permeabilization purposes. DNA
fragments were labeled with Click-iT® Tunel Alexa Fluor® following a modified version of
manufacturer's instructions (Invitrogen™-Life technology, Grand Island, NY). Parasites were
stained with 10 μl of propidium iodide (stock 1 mg/ml) and each sample was analyzed with a
Beckman Coulter FC500 flow cytometer (Beckman Coulter, USA) (Varela-Ramirez et al, 2011).
Parasites were incubated with DNase I as a positive control for producing breaks in the double
stranded DNA, and parasites treated with just solvent (DMSO) as a negative control.

Cell cycle analysis in L. major promastigotes
L. major promastigotes, 5x106, were individually treated with 2 μM of AM160 or AM162
complexes for 24 h at 28°C and their DNA content was examined via flow cytometry. Cell
pellets were obtained by centrifugation and fixed with chilled (-20°C) methanol, and incubated at
24

-20°C overnight. Then, cells were washed twice with PBS, followed by the addition of 20 μg/ml
of RNase A and incubated for 1 h at 37°C. Then, cells were labeled with propidium iodide, a
fluorescent DNA intercalator, for 20 min at room temperature and analyzed with Beckman
Coulter FC500 flow cytometer (Beckman Coulter, USA).

Statistical analysis
Each data point is presented as average with their corresponding standard deviation and standard
error for in vivo experiments. To establish statistical significance between two groups two-tailed
unpaired Student's t-test was performed. To designate whether two groups have statistical
significance, a value of P<0.05(*) was considered significant. Higher significant values P
<0.01(**), P<0.001(***) and P <0.0001(****) are also denoted. The graphs were attained using
Graph Pad Prism 5 Software (GraphPad Software, Inc., La Jolla, California).
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2.3

Results

Ruthenium-azole complex exerts anti-leishmanial activity in vivo
In our previous work, AM160 and AM162 exhibited potent in vitro leishmanicidal activity with
an excellent selectivity index (SI) [1, 37]. However, further characterization and study of AM160
and AM162 (Fig 2.1) is important to promote its evaluation as clinical candidates against
cutaneous leishmaniasis. A pilot experiment was set up to compare the efficacy of CTZ with the
Ru-CTZ complexes AM160 and AM162 in BALB/c mice. L. major metacyclic promastigotes
(1x105) were injected in the left hind footpad and mice groups were divided (n=3) as follows:
CTZ, C3 (metal control), AM160, AM162 and vehicle control group. After 14 dpi, the lesion
size was measured and intraperitoneal (i.p.) treatment with experimental compounds was
administered at a dosage of 4 mg/kg/day for 14 consecutive days. As observed in Fig 2.2.A, by
day 38 post-infection (endpoint of experiment), the AM160-treated animals exhibited reduction
in the size of CL lesions by 26%, as compared with vehicle-treated mice. Moreover, AM162
showed a better leishmanicidal effect than CTZ and reduced the group lesion size by 68% with
respect to the group treated with vehicle at the endpoint of experiment with a significant P value
of 0.00046. Therefore, we continued to investigate the effect of AM162 at a higher concentration
(6 mg/kg/day) in a hyper infection (1x106) with L. major. In this case, mice (n=3) were infected
and 21 dpi treated with AM162 for 10 consecutive days. Groups included AM162, naive group
(AM162-treated but non-infected), and vehicle control. AM162 was given i.p. at 6 mg/kg/day as
previously stated. In AM162-treated animals, comparison between day 21 (first day of AM162
treatment) and day 34 (last day of treatment and endpoint of experiment) of lesion sizes
increased from 1 to 1.25, respectively. In contrast, by doing the same analysis, but in vehicle
control-treated animals, the lesion size increased from 1 to 1.45. Findings revealed that AM162
treatment contributed to growth a smaller CL lesion sizes, as compared with vehicle-treated mice
26

(Fig 2.2B). Moreover, analysis of parasite load by identification of the minicircle kDNA of L.
major by quantitative real-time PCR was performed for the hyper infection experiment. A 10fold serial dilution with L. major promastigotes DNA was used to determine a standard curve
and the absolute parasite equivalent in 50 ng of DNA. Subsequently, the parasite load was
estimated from the DNA extracted from mice footpads from all groups described. As observed in
Fig 2.2C, AM162 treatment significantly (P= 0.0146) reduced parasite load in comparison with
groups treated with vehicle control. Moreover, no significant weight loss was observed after the
treatment with the experimental drugs (data no shown). Overall, this data suggests that even
though AM162 showed a moderate in vivo activity against L. major mice infection, the
compound was able to reduce the footpad lesions and parasite load by 50% or more, with no
significant toxicity.
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Fig 2.1 Chemical structures of clotrimazole (CTZ), AM160 and AM162 rutheniumclotrimazole complexes.

28

2.0

A

Vehicle Control

Lesion Size (mm)

CTZ
C3
AM160
AM162

1.5

1.0

0.5

P = 0.00046

0.0
0

5

10

15

20

25

30

Days Post-Infection

B

3.0

Lesion Size (mm)

2.5

Vehicle Control
Naive
AM162

2.0
1.5
1.0
0.5
0.0
15

20

25

30

35

Days Post-Infection

C

1.5×109

Parasite Equivalents

P = 0.0146
1.0×109

5.0×108

0.0
AM162

Vehicle Control

Experimental Groups

29

35

40

Fig 2.2 In vivo effect of Ru-CTZ complexes on cutaneous leishmaniasis in a murine model.
(A) Pilot experiment and lesion size (mm) of mice infected with 105 L. major metacyclic
promastigotes, followed by intraperitoneal treatment for 14 consecutive days of vehicle control
(50% v/v DMSO/PBS solution), or AM160, AM162, C3, CTZ at 4mg/kg/day. Statistical
significance was determined using Student’s t-test. P value of 0.00046 was obtained when
comparing AM162 with vehicle-treated mice. (B) Hyper infection experiment and lesion size
(mm) of mice infected with 106 L. major metacyclic promastigotes, intraperitoneal treatment for
14 consecutive days was applied: vehicle control (50% v/v DMSO/PBS solution), or AM162 at 6
mg/kg/day. (C) Quantitative real-time PCR of hyper infection experiment. Parasite equivalents
representing the target gene determined by real-time PCR of L. major minicircle kDNA present
in DNA extracted from footpads (50 ng). Statistical significance was determined using Student’s
t-test. P value of 0.0146 was obtained when comparing AM162 with vehicle-treated mice.
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Ruthenium-azole complexes induced phospholipid externalization
In early stages of metazoan apoptosis in unicellular organisms several alterations to the plasmatic
membrane are observed, including the externalization of phosphatidylserine (PS) [85] from the
inside to the outside of the plasma membrane. Recent evidence found through lipid analysis,
determined that Leishmania promastigotes lack PS [86]. Despite this fact, annexin-V was able to
bind other phospholipid species such as phosphatidylinositol [86] and phosphatidylethanolamine
and cardiolipin in Leishmania promastigotes after permeabilization with miltefosine probably as
a consequence of alterations or changes in the transbilayer plasma membrane lipid arrangement
[76]. Therefore, annexin-V conjugated with Alexa Fluor 488 was used to detect positive L. major
promastigotes cells with externalization of phospholipids. In addition, PI was added in order to
be able to differentiate between apoptotic cells (annexin-V positive, PI negative), necrotic cells
(annexin-V negative, but PI positive), and live cells (negative to both annexin-V and PI). As
shown in Fig 2.3A, in comparison to the negative control treated with 1% DMSO the percentage
of apoptotic cells (annexin-V+, PI-) significantly increased following the treatment with AM160
and AM162 for 24 h at a concentration of 2 μM for all the compounds. In addition, none of the
Ru-azole compounds showed significant necrotic percentages in comparison with the positive
control treated with hydrogen peroxide. This data suggests that our compounds produced an
apoptotic-like effect in L. major promastigotes. These findings indicate that the compounds exert
selectively their anti-leishmanial activity primarily via apoptosis.
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Fig 2.3 Ru-CTZ complexes induced phospholipids externalization in L. major
promastigotes after 24 h of treatment at 2 μM. (A) Percentage of apoptotic and necrotic
parasites treated with the compounds and controls. (B) Representative flow cytometry
scatterplots of the compounds and controls, cells were stained with annexin V-Alexa Fluor 488
and propidium iodide. P values ranges, P <0.01(**).
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Ruthenium-azole complexes triggered dissipation of mitochondria membrane potential (Δψm)
Depolarization of mitochondria transmembrane potential (Δψm) is an initial biochemical facet
implying activation of the intrinsic apoptotic pathway, as the initial triggering signal of apoptosis
[87]. In addition, it has been proven to be an important feature for cell death in protozoa parasites
such as Leishmania [88]. To examine the potential dissipation of Δψm in cells exposed to the
experimental compounds, the membrane-permeant JC-1 reagent (Mitoprobe™ kit; Life
Technologies) and flow cytometric protocol were employed. JC-1 is a cationic dye forming
aggregates in the mitochondria of healthy cells, emitting red fluorescence signal. In cells with
dissipated Δψm JC-1 is unable to make aggregates, as consequence JC-1 remains as monomer
emitting green fluorescent signal. In addition, carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) a proton ionophore was concurrently evaluated at 50 μM as a positive control for
dissipation of mitochondrial membrane potential. As depicted in Fig 2.4A, cells treated with
AM160 or AM162 compounds caused a concentration-dependent loss in Δψm in comparison to
the negative control treated with 1% DMSO. An increase of more than 2-fold (from 30.8 % to
about 80%) was observed with depolarized mitochondria in promastigotes treated with 0.25 µM
of AM160 or AM162, as compared with the vehicle control (1% DMSO). This depolarized
mitochondria percentage incremented with higher concentrations (0.50 and 1 uM) of both
AM160 and AM162. The JC-1 fluorescence emission shift from red (aggregates) to green
(monomers) was observed in promastigotes treated with the two AM160 and AM162 Ru-azole
compounds, as compared to the negative control (Fig 2.4B). Therefore, our findings suggest that
Ru-azole compounds are inducing, in a dose-dependent manner, an apoptosis-like cell death in L.
major promastigotes and that this early event is utilized to initiate the intrinsic pathway
evidenced by disruption of Δψm.
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Fig 2.4 Ru-CTZ-mediated cytotoxicity involves Δψm disruption in L. major promastigotes.
(A) Percentage of JC-1 green fluorescence L. major promastigotes treated for 6 h with the Ruazole compounds. Negative control 1% DMSO and positive control CCCP. (B) Representative
flow cytometry plots for JC-1 assay. P values ranges, P <0.01(**) and P <0.001(***).
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DNA fragmentation after treatment of Ru-azole compounds
During apoptosis the cleavage patterns of genomic DNA are typical of internucleosomal DNA
digestion by an endogenous nuclease, which is considered a late biochemical hallmark of
apoptotic cell death [88]. The terminal deoxynucleotidyl transferase enzyme mediated dUTP end
labeling (TUNEL) assay detects the DNA fragmentation at a single-cell level, thereby allowing a
better evaluation of the apoptotic cell fraction. In this case the Click-iT® TUNEL Alexa Fluor®
assay was used to evaluate DNA fragmentation of promastigotes treated with AM160 and
AM162. As observed in Fig 2.5, the Ru-CTZ compounds showed a similar pattern of DNA
fragmentation as the one observed in the positive control DNase I. Therefore, these data suggest
that the Ru-azole complexes were able to induce DNA fragmentation leading to an apoptotic-like
death in L. major promastigotes.
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Fig 2.5 Ru-CTZ complexes induce DNA fragmentation. (A) Flow cytometry scatterplots
illustrating the detection of DNA strand breaks in apoptotic L. major promastigotes by TUNEL
assay. Apoptotic cells characterized by high frequency of DNA strand breaks producing the
exponential scale of Y coordinate observed in the positive control treated with DNase I.
Apoptosis pattern observed after treatment of AM160 and AM162 at 2 μM for 6 h.
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Ruthenium-azole compounds alter cell cycle profile
In order to determine if the compounds alter the cell cycle profile of L. major promastigotes,
flow cytometric analysis was performed after 24 h of incubation with 2 μM AM160 or AM162.
During analysis of cell cycle distribution profile, quantifying cellular DNA content via flow
cytometry, it is relatively easy to identify a sub-G0/G1 or hypodiploid peak, indicator of the cell
population carrying fragmented DNA; a late facet of apoptotic cell death [89]. Promastigotes
treated for 24 h with AM160 or AM162 (2 µM) exhibited 73.4% or 90.7% of sub-G0/G1
population, respectively; whereas cells treated with solvent control (DMSO) displayed just 7.7 %
of the same sub-G0/G1 population (Fig 2.6). These findings indicate that Ru-azole compounds
caused an increase in the percentage of sub-G0/G1 peak, which is interpreted as promastigotes
carrying fragmented DNA. Concurrently, Ru-azole complexes reduced the percentages of both
G0/G1 and S/G2/M population. Thus, Ru-azole compounds alter the cell cycle profile and use
the DNA fragmentation pathway as their mechanism to inflict death in L. major promastigotes.
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Fig 2.6 Ru-azole compounds provoked DNA fragmentation in L. major promastigotes after
24 h of exposure, evidenced by increment in the sub-G0/G1 phase. The percentage
distribution of cells for each defined subpopulation of the cell cycle phases are depicted as
follow; (A) sub G0/G1 (hypodiploid; apoptotic population); (B) G0/G1 (diploid); and (C)
S/G2/M (hyperdiploid/tetraploid). (D) Representative flow cytometric histograms of cells treated
with the experimental compounds and 1% DMSO. P values ranges, P <0.01(**) and P
<0.0001(****) for the apoptotic population.
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2.3

Discussion

Leishmaniasis is a neglected tropical disease that affects millions of people worldwide.
Despite recent advances, poor efficacy and high toxicity of the limited available treatment
options demonstrate the need for the development of new chemotherapeutic agents to treat this
disease. In an effort to contribute to this concern, novel Ru-azole complexes were synthetized,
characterized and tested as chemotherapeutic agents against L. major [1, 37]. Initially, we used a
high-throughput screening approach to evaluate the cytotoxicity of the Ru-CTZ compounds in
different mammalian cells and viability of L. major promastigotes. To our satisfaction, two
compounds displayed potent leishmanicidal activity in both L. major promastigotes and
intracellular amastigotes with no significant cytotoxicity towards mammalian cells. In addition,
we observed that Ru-CTZ compounds improved the anti-leishmanial effect in comparison with
CTZ alone in vitro [1, 37]. Nowadays, as a general rule for a successful drug candidate, in vivo
experiments are necessary. Therefore, in the present report we sought to study the therapeutic
efficacy in vivo of the Ru-CTZ compounds in mouse model of CL. Treatment with 4 mg/kg/day
of AM162 reduced the lesion size in the murine model of CL by a 68%, a markedly better effect
than CTZ alone or a RuII complex not containing CTZ (C3). In addition, in a hyper infection
experiments and using a dosage of 6 mg/kg/day of AM162, the parasite burden was significantly
reduced (P=0.0146) (Fig 2.2C). Therefore, these findings indicate that AM162 possess efficient
anti-leishmaniasis activity in vivo, and that the combination of the metal and CTZ in a single
molecule is responsible for the anti-parasitic activity.
Additionally, the mechanism of action of current anti-leishmanial drugs remains obscure
or unknown. Moreover, with the establishment of the leishmanicidal activity of the Ru-CTZ
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compounds observed in previous studies is now important to understand their mechanism of
action in order to facilitate the design of new chemotherapeutic strategies against leishmaniasis.
Apoptosis is considered a feature of multicellular organisms, and it is well defined as a form of
programmed cell death in which a series of events leads to self-destruction without inducing
inflammatory responses in vivo. In contrast with apoptosis, necrosis results from acute tissue
injury producing an inflammatory response [90]. In Leishmania spp., it has also been suggested
that apoptosis may be a useful mechanism of cell death to evade an inflammatory response and
therefore prevent the establishment of an effective immune response, allowing in this way the
intracellular survival form of non-apoptotic parasites [91]. It has been reported that several antileishmanial drugs such miltefosine [92] or artemesinin [77] kill the parasite through an
apoptotic-like pathway. Therefore, in the present study we sought to investigate the possible
mechanism of cell death induced by the AM162 complex in L. major.
Phosphatidylserine is mainly situated in the inner leaflet of the plasmatic membrane
bilayer in healthy cells and when is translocated to the external membrane leaflet, serves as a
sensitive indicator to identify and quantify cells experiencing apoptosis ([85]. Annexin V protein,
conjugated with a fluorophore, is a routinely used reagent due to the fact that it possesses a high
affinity for PS and serves to identify cells with externalized PS via flow cytometry in a live-cell
manner. Promastigotes exposure to AM160 or AM162 for 24 h, exhibited phospholipid
externalization after examination by a flow cytometer protocol (Fig 2.3), thus suggesting that
both Ru-azole complexes use the apoptotic-like pathway to provoke cell death.
Apoptotic cell death can be trigger via two main pathways, intrinsic/mitochondrial and
extrinsic/death receptor. Previously, CTZ was observed to decrease the mitochondrial membrane
potential in L. major infantum chagasi promastigotes, in addition to low alteration of their
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plasma membrane [78]. However, the percentage of mitochondrial membrane potential exerted
by CTZ treatment in L. major infantum chagasi promastigotes was not significant in comparison
with their control [78]. Here, it was explored whether ruthenium-clotrimazole complexes AM160
and AM162 were able to significantly initiate the activation of the intrinsic pathway, which is
evidenced by dissipation of the mitochondria membrane potential. L. major promastigotes were
exposed to AM160 or AM162 and after staining with JC-1 were immediately analyzed via flow
cytometer. AM160 and AM162 complexes were able to provoke mitochondria depolarization
after 6 h of incubation (Fig 2.4), suggesting that the intrinsic pathway is implicated in their
mechanism of action to induced cell death.
DNA fragmentation is one of the best-recognized events that occur in the progression of
apoptosis through the activation of endonucleases, such as caspase activated deoxiribonuclease
and is a late biochemical phase in apoptosis [89]. To reinforce previous findings, TUNEL assay
was performed to investigate if the Ru-CTZ complexes provoke DNA fragmentation to induce
cell death. After exposure to AM160 or AM162, promastigotes were processed according with
the TUNEL protocol and analyzed by flow cytometer. Results indicate that both AM160 and
AM162 provoked DNA fragmentation on promastigotes after treatment exposure (Fig 2.5).
Additionally, cell-cycle profile and DNA fragmentation is often measured concomitantly
via cellular DNA content, using a fluorescence nucleic acids intercalator dye [86]. When
utilizing this strategy, a selective increment in the sub G0/G1 (hypodiploid) population, localized
to the left of the G0/G1 peak could be identified, which is interpreted as cells carrying
fragmented DNA. Promastigotes exposed to both AM160 or AM162 for 24 h exhibited an
alteration in the cell cycle profile, proved by decreasing both G0/G1 and S/G2/M populations,
concomitantly associated with an increase in the sub-G0/G1 population (Fig 2.6). Thus, the
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results here corroborated our findings obtained from the TUNEL assay, indicating that the two
Ru-azole complexes induce DNA fragmentation as their mechanism of action.
Overall, the ruthenium-clotrimazole AM162 complex has demonstrated to be an efficient
compound for the treatment of cutaneous leishmaniasis in a murine model, with imperceptible
toxicity to the experimental animals. Additionally, both AM160 and AM162 exhibited proapoptotic-like properties, implicating phospholipids externalization, mitochondrial depolarization
and DNA fragmentation pathway, as its mechanism to induce cell death in L. major parasites;
encompassing early and late hallmarks of apoptosis. The effects observed of AM162 in the in
vivo model point us to the synthesis of new chemical formulations, AM162-derived analogs,
with the aim to increase its solubility and efficacy against this neglected disease. Furthermore,
since the AM162 complex showed the best in vivo anti-parasitic activity, new delivery
formulations of this compound are currently in development in our laboratory for further preclinical studies.
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Chapter 3: An α-Gal-containing neoglycoprotein-based vaccine partially
protects against murine cutaneous leishmaniasis caused by Leishmania major

∗
3.1

Introduction

Cutaneous leishmaniasis (CL) is a neglected, vector-borne disease caused by several
species of the protozoan parasite, Leishmania. CL currently affects up to 1.2 million people
worldwide annually [4], although due to stigma and psychological burden post-infection, its
prevalence has been recently estimated to be around 40 million [93]. Because of conflict and
large human displacement, the disease is currently hyperendemic in the Middle East [94, 95].
Spread by the bite of an infected sandfly, CL is characterized by localized cutaneous ulcers with
different clinical presentations [5]. Currently, there is no commercially available preventive or
therapeutic human vaccine for CL and, depending on the region, vector control is insufficient or
nonexistent. Furthermore, when prevention fails, infected patients rely on expensive and highly
toxic drugs (mainly antimonials), which are costly and have become ineffective in some areas
due to emerging resistant parasite strains [72]. Despite current advances, the development of a
safe, affordable and fully protective anti-leishmaniasis vaccine continues to be a challenge.
Experimental vaccines have been explored; however, they either lack the ability to confer full
sterile protection against parasite challenge, show outcomes which considerably differ by

∗ Note: This chapter is the basis for the manuscript 1 (see list of publications and manuscripts): E. Iniguez, N. S. Schocker, K. Subramaniam, S.
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Maldonado. Aα-Gal-terminating containing neoglycoprotein-based vaccine protects against murine cutaneous leishmaniasis caused by
Leishmania major. Plos Neglected Tropical Diseases. Submitted.
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location, and/or the clinical trial was abandoned due to safety regulations [41, 96, 97]. Therefore,
development of a fully protective vaccine against CL is much needed.
During the life cycle of L. major or L. tropica, the main species responsible for CL in the
Old World, parasites must survive and proliferate inside the hostile environment of human
macrophages. They use different evasion mechanisms, including the formation of a protective
glycocalyx barrier that is mainly composed of protein-free glycosylphosphatidylinositol (GPI)
anchors, known as glycoinositolphospholipids (GIPLs), among other surface glycoconjugates
[62-66]. In L. major, highly abundant Type-II GIPL-2 and GIPL-3 are capped with terminal,
non-reducing

α-galactopyranosyl (α-Galp or α-Gal) residues with different structural

configurations (Galpα(1,3)Galƒβ-R and Galpα(1,6)Galpα(1,3)Galƒβ-R, respectively; where R is
the remaining GPI anchor) [68]. These glycolipids are conserved throughout the parasite’s life
cycle, and are highly abundant (i.e., >1010 copies/cell) in the amastigote (mammalian) stage [65].
Due to the inactivation of the α1,3-galactosyltransferase (α1,3GalT) gene [69], terminal, nonreducing and linear α-Gal epitopes are absent and, therefore, highly immunogenic to humans and
Old World nonhuman primates. Thus, healthy human individuals normally produce anti-α-Gal
antibodies (also known as normal anti-Gal antibodies) against α-Gal epitopes found in
lipopolysaccharides of enterobacteria [98-100]. On the other hand, during infections with
Trypanosoma cruzi, Leishmania spp., or Plasmodium spp., parasite-specific anti-α-Gal
antibodies are elicited [101-108]. These antibodies have different specificities than normal antiα-Gal antibodies. For instance, T. cruzi-specific anti-α-Gal antibodies have been used as reliable
biomarkers for diagnosis and follow-up of chemotherapy of patients with chronic Chagas disease
[109, 110]. More recently, similar roles and applications have been proposed for anti-α-Gal
antibodies produced during CL [107]. In both acute and chronic phases of Chagas disease, T.
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cruzi-specific IgM and IgG anti-α-Gal antibodies are trypanolytic and protective [103, 106, 111],
and a vaccine based on the major parasite α-Gal epitope has been proposed [112]. In
Plasmodium infections in children, however, IgM but not IgG anti-α-Gal antibodies appear to
have a protective effect [108]. Although the levels of anti-α-Gal antibodies are very high in
Leishmania infections [102, 104, 105, 107], it has not yet been demonstrated whether these
antibodies have any protective role. More recently, Jaurigue and Seeberger [57] have proposed
α-Gal epitopes as vaccine candidates against Leishmania spp., and other major protozoan
parasites. In this study, we explore this possibility by evaluating neoglycoproteins (NGPs)
containing synthetic α-Gal epitopes in different configurations, as potential preventive L. major
vaccine candidates in the α1,3-galactosyltransferase-knockout (α1,3-GalT-KO) mouse model,
which does not express terminal α-Gal epitopes on their cells [113, 114].
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3.2

Materials and methods

Ethics Statement
Animal procedures were performed according to NIH guidelines and the appropriate protocol
(A-201209-1) approved by UTEP’s Institutional Animal Care and Use Committee (IACUC). The
Institutional Review Board (IRB) protocol was approved by IRB Committee of the Liverpool
School of Tropical Medicine (LSTM) (Research Protocol 15.037). Written informed consent was
obtained from all participants. Only adults participated in the study. For the collection of human
samples, ethical approval (12·06R) was granted by both the Liverpool School of Tropical
Medicine and the KSA Ministry of Health Ethical Committees.

Mice
C57BL/6 α1,3-Galactosyltransferase-knockout (α1,3GalT-KO) mice [113, 114] were kindly
donated by Prof. Peter J. Cowan, St. Vincent’s Hospital Melbourne and University of
Melbourne, Australia. Animals were bred and maintained under biosafety level 2 (BSL-2),
pathogen-free conditions at the Laboratory Animal Resources Center (LARC) at UTEP. Six to
eight-week old female α1,3GalT-KO mice were used for all experiments.

Human sera
Human serum samples from adult patients with L. major active (n=5) or cured CL (n=5)
infections, or adults with heterologous (non-CL) infections (n=5) were obtained from the AlAhsa region, Kingdom of Saudi Arabia (KSA), which is exclusively endemic for L. major CL
[115]. Detailed information on each serum sample regarding sex, age, and race of the patient was
not available for this study.

Parasites
Promastigote forms of transgenic L. major expressing firefly luciferase (L. major-luc) (Lmj47

FV1-LUC-TK [L. major strain Friedlin], clone V1) [116, 117], kindly donated by Prof. Stephen
M. Beverley (Washington University in St. Louis, MO), were grown at 28°C in M199 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Thermo Fisher
Scientific, Waltham, MA) and 1% penicillin-streptomycin. Infective metacyclic promastigote
forms were purified by Ficoll gradient at stationary phase (3-5 days), as previously described
[80].

Neoglycoproteins
The NGPs Galα(1,3)Galβ(1,4)Glcβ-BSA (NGP1B), Galα-BSA (NGP3B), Galα(1,6)Galβ-BSA
(NGP5B),

Galα(1,2)Galβ-BSA

(NGP8B),

Galα(1,6)[Galα(1,2)]Galβ-BSA

(NGP11B),

Galα(1,4)Galβ-BSA (NGP12B), Galβ-BSA (NGP13B), and Galα(1,3)Galα-BSA (NGP17B)
were obtained as previously described [118]. Briefly, mercaptopropyl glycan derivatives were
synthesized and covalently coupled to commercially available maleimide-activated bovine serum
albumin (BSA) (Pierce, Thermo Fisher Scientific) to generate their respective NGPs. A
schematic representation of the NGP synthesis is shown in Fig 3.1A.
The glycan load for each NGP was measured using matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF-MS) (Axima, Shimadzu), as described [112].
Lyophilized underivatized BSA (control) or NGP was first diluted in sterile deionized water to a
1.0-1.5 mg/µL solution. Pre-loading mix was prepared by adding 5 µL of diluted NGP or BSA,
2.5 µL of sinapinic acid (Sigma-Aldrich), and 1.5 µL acetonitrile:water (2:1, v/v) with 0.1%
trifluoroacetic acid (Thermo Fisher Scientific). Next, 0.5 µL of pre-loading mix was applied to
MALDI-plate spot and allowed to air dry. Once dried, 100 shots were fired per spot and 20
spectra were acquired. The glycan load per NGP molecule was calculated by subtracting the

48

BSA average molecular mass from the NGP average molecular mass, and dividing it by the
nominal molecular mass of one glycan-linker unit (636 Da) (Fig 3.1B).
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Fig 3.1 Schematic representation of NGP synthesis. (A) Conjugation of mercaptopropyl
saccharide derivative (disulfide glycan) to maleimide-activated BSA to produce the NGP
Galα(1,6)Galβ-BSA (NGP5B). For simplification, the linker and lysine side chain are omitted
from all NGP nomenclatures used in this study. (B) MALDI-TOF-MS analysis of BSA before
and after maleimide-derivatization and glycan coupling to generate NGP5B. Doubly-charged
([BSA]2+ and [NGP]2+) and singly-charged ([BSA]+ and [NGP]+) ions of BSA and NGP are
indicated. Lys, lysine.
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Immunizations
The NGPs Galα(1,6)Galβ-BSA (NGP5B), Galα(1,4)Galβ-BSA (NGP12B), and Galα(1,3)GalαBSA (NGP17B), obtained as described above, were first redissolved in sterile deionized water
and then diluted in sterile phosphate-buffered saline (PBS), pH 7.4, immediately prior to
immunizations. Phosphorothioate-modified oligodeoxynucleotide (ODN) sequence 1826
containing two CpG motifs (5’-TCCATGACGTTC-CTGACGTT-3’) (CpG ODN or CpG
adjuvant) was obtained from InvivoGen (San Diego, CA) and was dissolved in endotoxin-free,
0.9% NaCl solution, at 2 mg/mL. NGP12B, NGP17B, and NGP5B were administrated at 10
μg/dose in a final volume of 200 µL PBS. NGP5B was also administrated at 10 μg/dose in
combination with CpG (NGP5B+CpG) adjuvant at 20 μg/dose in a final volume of 200 µL.
Control groups were immunized with CpG (20 μg/dose) or PBS alone in a final volume of 200
µL. A total of four immunizations were subcutaneously administrated at 7-day intervals.

Chemiluminescent enzyme-linked immunosorbent assay (chemiluminescent ELISA) with CLinfected patients
Chemiluminescent ELISA [107] was performed for screening the IgG response to various α-Galcontaining NGPs in patients with active or cured CL infections, or patients with heterologous
(non-CL) skin infections. Briefly, 96-well Nunc polystyrene microplates (Thermo Scientific)
were coated overnight at 4⁰C with 250 ng/well of each NGP in 200 mM carbonate-bicarbonate
buffer, pH 9.6 (CBB buffer). Plates were blocked with 100 µL 1% BSA-PBS (BSA, SigmaAldrich, St. Louis, MO) for 1 h at 37⁰C before washing three times with PBS-0.05% Tween 20
(Sigma-Aldrich) (PBS-T). Pools of human sera at 1:100 dilution (in PBS) were analyzed in
triplicate. Plates were incubated for 1 h at 37⁰C. Goat anti-human IgG antibody (Sigma-Aldrich;
50 µL, 1:1000 dilution) in PBS was added and incubated for 1 h at 37⁰C. Donkey biotinylated
anti-goat IgG conjugate (Thermo Fisher Scientific; 50 µL, 1:1000 dilution) in PBS was added
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and plates were incubated for 1 h at 37⁰C. Horseradish peroxidase (HRP)-streptavidin
(Invitrogen; 50 µL, 1:2000 dilution) in PBS was added and plates were incubated for 30 min at
37⁰C. Plates were washed three times between steps with PBS-T, except before blocking. The
reaction was developed with Super-Signal Chemiluminescent Substrate (Thermo Fisher
Scientific) at 1:8 dilution in 50 µL CBB buffer and relative luminescence units were measured
using a FLUOstar Omega microplate reader (BMG LabTech, Baden-Württemberg, Germany).
Serum samples used to generate the pools were selected at random from three different patient
groups: cured CL infections, active CL infections, or heterologous diseases (control group).
Heterologous controls included patients that had skin abnormalities that mimicked CL (e.g.,
eczema) but without the Leishmania parasite. Wells with PBS (no serum controls) were added to
address background nonspecific reactivities.

Chemiluminescent ELISA with sera from vaccinated α1,3GalT-KO mice
Blood was obtained from all animals by facial vein puncture, and serum was obtained by
centrifugation (2,500 xg, 10 min, 4oC). To assess the humoral immune response, levels of
specific anti-α-Gal antibody titers were determined by chemiluminescent ELISA, as previously
described [107, 118]. MaxiSorp Nunc polystyrene microplates (Thermo Fisher Scientific) were
coated with 125 ng/well of each NGP in CBB buffer and incubated overnight at 4˚C. Plates were
blocked with 200 µL 1% BSA-PBS, and incubated with mouse sera (50 µL) from vaccinated or
control groups at 1:100 dilution for 1 h at 37oC. Donkey biotinylated anti-mouse (Pierce, Thermo
Fisher Scientific) was used at 1:2000 dilution in 1% BSA/PBS with 0.05% Tween 20 (1%
BSA/PBS-T). NeutrAvidin-HRP (Pierce, Thermo Fisher Scientific) was used at 1:5000 dilution
in 1% BSA/PBS-T. Plates were washed 3x between steps with PBS-T, except before blocking.
The reaction was developed with SuperSignal Pico Chemiluminescent Substrate (Pierce, Thermo
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Fisher Scientific). Luminescence (in RLUs) was measured by Luminoskan luminometer
(Thermo Fisher Scientific).

α-Galactosidase treatment
To test the specificity of the IgG antibodies elicited in mice immunized with NGP5B or
NGP5B+CpG, immobilized NGP5B used as antigen was pretreated with green coffee bean αgalactosidase (G8507, Sigma-Aldrich), as previously described [107]. First, MaxiSorp Nunc
polystyrene microplate (Thermo Fisher Scientific) wells were coated with 125 ng/well of
NGP5B in CBB buffer and incubated overnight at 4°C. The plate was blocked with 200 µL 5%
skim milk-PBS for 1 h at 37°C, and washed three times with 200 µL PBS-T. In parallel, two
hundred microliters of α-galactosidase (in ammonium sulfate suspension, ≥9 units/mg protein)
were centrifuged at 10,000 xg for 10 min at 4°C to remove the excess ammonium sulfate. The
supernatant was discarded and the pellet containing the enzyme was gently redissolved in icecold 100 mM potassium phosphate buffer (pH 6.5). Fifty microliters of the enzyme solution
(0.002 units/µL) were added to each well, and the plate was incubated for 24 h at 37°C. The
microplate was washed twice with 200 µL PBS-T and the chemiluminescent ELISA was
performed as described above.

Parasite challenge
Six to eight-week old female α1,3GalT-KO mice (n=3 per group) were inoculated with 1 x 105 L.
major-luc metacyclic promastigotes in the left hind footpad 3 weeks after last immunization.
Mice lesion size (mm) was monitored weekly with a digital caliper.

In vivo bioluminescence imaging and weight monitoring
To measure disease progression, in vivo bioluminescence imaging of L. major-luc was acquired.
Mice were injected intraperitoneally (i.p.) with 150 mg.kg-1 D-luciferin (Gold Biotechnology, St.
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Louis, MO) and anesthetized with 2.5% gaseous isoflurane in oxygen. Images were acquired 15
min after luciferin injection using IVIS Lumina III in Vivo Imaging System (PerkinElmer,
Waltham, MA). Additionally, for any sign of toxicity mice were periodically weighed, and
weight change was normalized using the initial mouse weight.

Parasite load by quantitative PCR
At experimental endpoint, mice were sacrificed by CO2 overdose and infected footpads from all
groups were harvested. Genomic DNA from 20 to 30 mg of tissue was extracted with High Pure
PCR Template Preparation Kit following the manufactures protocol without modifications
(Roche Molecular Systems, Indianapolis, IN). As internal control, a linearized pUC57 plasmid
containing a sequence from Arabidopsis thaliana was spiked before all DNA extractions as
previously described [119]. Parasite load was measured by absolute quantification based on a
standard DNA curve ranging from 0.5 to 105 L. major parasite equivalents/mL. A standard curve
was produced by extracting DNA from a 20 to 30 mg tissue fragment, spiked with 105 L. major
promastigotes (spiked DNA). In parallel, DNA was extracted from 20 to 30 mg of tissue
fragment from uninfected mice (negative control DNA). Afterwards, spiked DNA was 10-fold
serially diluted in the negative control DNA. Amplification of 120 bp-fragment from the
kinetoplast DNA of L. major was performed using 100 nM of forward primer (5’CTTTTCTGGTCCTCCGGGTAGG-3’),
CCACCCGGCCCTATTTTACACCAA-3'),
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of
nM

of

reverse

primer

TaqMan

probe

(5’(FAM-

TTTTCGCAGAACGCCCCTACCCGC-TAMRA); a total of 100 ng of DNA was added to a
reaction in a final volume of 20 μL [120, 121]. The internal amplification control (IAC) was
amplified using 100 nM of forward primer (5’-ACCGTCATGGAACAGCACGTA-3’), 100 nM
of reverse primer (5’- CTCCCGCAACAAACCCTATAAAT-3’), and 50 nM of TaqMan probe
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(VIC-AGCATCTGTTCTTGAAGGT-NFQ-MGB). PCR conditions consisted of 50°C for 2 min,
94°C for 10 min, followed by 45 cycles at 94°C for 15 sec and 55°C for 1 min. Samples were run
in triplicate in Step One Plus Real Time PCR System (Applied Biosystems).

Serum cytokine profile
Th1, Th2, and Th17 cytokines (IL-12p40, IL-2, IFN-γ, TNF-α, IL-5, IL-4, IL-10, IL-6, and IL17) were analyzed using multiplex kit, MILLIPLEX Mouse Cytokine Magnetic Bead Panel
(EMD Millipore, Billerica, MA). Sera (at 1:2 dilution) from all immunized groups and controls
were analyzed at 3 weeks after last immunization, prior to challenge (day 0), following the
manufacturer’s protocol.

Immunoglobulin isotyping
Additionally, antibody levels of mouse IgG1, IgG2a, IgG2b IgG3, and IgE specific to NGP5B
were analyzed by ELISA at boost 3 (B3, day -21) and experimental endpoint (day 43). Briefly,
96-well Nunc polystyrene microplates (Thermo Fisher Scientific) were coated overnight at 4⁰C
with 125 ng/well of NGP5B in CBB buffer. Plates were blocked with 200 µL 1% BSA-PBS for
1 h at 37⁰C. Mouse serum was diluted at either 1:400 (B3) or 1:100 (endpoint) dilution in PBS.
To detect the various mouse IgG subtypes secondary antibodies conjugated to HRP were used
(goat anti-mouse IgG1-HRP, goat anti-mouse IgG2a-HRP, goat anti-mouse IgG2b-HRP, and
goat anti-mouse IgG3-HRP). All secondary antibody conjugates were from Abcam (Cambridge,
MA). The antibodies were diluted 1:2000 in PBS and 100 µL was added to each well. Plates
were incubated for 1 h at 37⁰C, followed by washing three times with PBS-T (200 µL) between
the steps. The reaction was developed with 100 µL Super-Signal Chemiluminescent Substrate
(Thermo Fisher Scientific) at1:8 dilution in CBB buffer and read using a FLUOstar Omega
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microplate reader (BMG LabTech). A pool of sera from α1,3GalT-KO mice was used as
negative control. Biological replicates were run for each test group.

Lytic assay of L. major metacyclic promastigotes
L. major metacyclic promastigotes (200 µL of 1 x 106 parasites/ml DMEM) were pre-incubated
with 10% fresh sera (with active complement) from mice immunized with NGP5B,
NGP5B+CpG, CpG, or PBS. Prior to the lytic assay, in selected incubation mixtures,
complement was heat-inactivated at 56˚C for 30 min before adding serum to the parasites. 0.5
µg/mL propidium iodide (PI; Sigma-Aldrich) diluted in deionized water was added after 10 min
of parasite-serum incubation, followed by additional 30-min incubation at room temperature
(RT) for all experimental samples. A total of 5,000 events were analyzed by flow cytometry
using a Gallios Flow Cytometer (Beckman Coulter). The percentage of PI-positive events (=% of
dead parasites) were graphed.

CD4+ and CD8+ T cell analysis by flow cytometry
Three weeks after the last immunization prior to challenge (day 0) or post-challenge (endpoint,
day 43), splenocytes were harvested from mice (n=3 per group) and cultured in freshly prepared
Dulbecco’s modified Eagles’ medium (DMEM), supplemented with 10% heat-inactivated FBS
(Gibco, Thermo Fisher Scientific), 1% penicillin-streptomycin, and 0.5 mM 2-mercaptoethanol
(2-ME). After splenocyte harvesting, ten milliliters of red blood cell lysis solution (0.83%
ammonium chloride, 0.1% potassium bicarbonate, 0.04% EDTA, pH 7.4), was added to cells for
10 min, and splenocytes were cultured in 12-well flat-bottom plates (Corning Costar, Thermo
Fisher Scientific) and stimulated in vitro with 20 µg/ml of antigen (NGP5B or NGP5B+CpG) at
37 °C, in 5% CO2 atmosphere, for 24 h. In brief, Fc-gamma receptor (FcγR) was blocked with
10% heat-inactivated naïve α1,3GalT-KO mouse serum and cells were stained with
56

fluorochrome-conjugated antibodies PE-Cy7-labeled anti-CD3e, PE-labeled anti-CD4, FITClabeled anti-CD8, APC-labeled anti-CD44, and Alexa Fluor 700-labeled anti-CD69 (all
conjugates were from BD Bioscience, San Jose, CA), along with the appropriate isotype controls
(BD Bioscience) for 30 min at 4°C. Cells were washed with PBS with 1% BSA plus 0.09%
sodium azide, and fixed with 1% paraformaldehyde. A total of 10,000 events were acquired
using a Gallios Flow Cytometer (Beckman Coulter) and analyzed by Kaluza Software (Beckman
Coulter). Gates were set for cells, followed by lymphocytes (CD3e-Pe-Cy7 labeling) using
forward and side scatter properties, and the frequencies and percentages of activated CD4+ and
CD8+ T cells were obtained on CD3+ T cells.

Statistical analysis
Each data point is presented as average of triplicate determinations with their corresponding
standard error of the mean (S.E.M.). Student t-test, One-way ANOVA, or Two-way ANOVA
were employed in the statistical analysis. Graphs and statistical analysis were attained using
Graph Pad Prism 6 Software (GraphPad Software, Inc., La Jolla, CA).
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3.3

Results

Evaluation of synthetic neoglycoproteins as potential biomarkers in L. major-infected
individuals
The antigenicity and specificity of eight NGPs containing different synthetic α-Gal epitopes were
evaluated by chemiluminescent ELISA using pools of sera from L. major-infected patients with
active or cured CL infections, from an endemic region of Saudi Arabia. Heterologous controls
included patients who had skin abnormalities that mimicked CL (e.g., eczema) but without
Leishmania parasites (Fig 3.2). NGP17B (Galα(1,3)Galα-BSA), NGP12B (Galα(1,4)GalβBSA), and NGP5B (Galα(1,6)Galβ-BSA) showed the best differential reactivity between active
CL vs. cured CL infection, and active CL vs. heterologous infection. Although highly reactive
with the serum pool from patients with active CL infection, NGP8B and NGP11B showed higher
cross-reactivity with the heterologous control. Conversely, NGP3B and NGP1B showed little or
no differential reactivity between active and cured CL infection. Together, these results suggest
that NGP17B, NGP12B, and NGP5B are immunogenic and potential biomarkers of active CL
infection.
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1.3x ****
4.8x ****
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Fig 3.2 α-Gal-NGPs as biomarkers of active CL in patients with L. major infection.
Assessment by chemiluminescent ELISA of α-Gal-containing NGPs and controls (Cysteine-BSA
and Galβ-BSA) were immobilized on a microplate and reacted with pools of sera (at 1:100
dilution) from patients with active or cured CL, or heterologous skin (non-CL) infections (n=5
per group, randomly selected) from an endemic region (Saudi Arabia), as described [107]. RLU,
Relative luminescence units. Error bars indicate S.E.M. of triplicate determinations. The fold
difference in reactivity between active CL vs. cured CL, and active CL vs. heterologous infection
are indicated. Two-way ANOVA with Tukey’s multiple comparisons: ns, non-significant; (*),
P<0.05; (**), P<0.01; (***), P<0.001; (****), P<0.0001.
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Synthetic NGPs as vaccine candidates against L. major infection
The relative high specificity and antigenicity of NGP12B, NGP17B, and NGP5B in active CL
infection led us to interrogate whether these NGPs would also be able to induce protective
response against in vivo L. major infection. To this end, we used C57BL/6 α1,3GalT-KO mice,
which lack α-Gal epitopes in their cells and tissues, therefore mimicking human antibody
responses to these epitopes [113, 122]. Animals (n=6 per group) were subjected to four
immunizations of NGP12B, NGP17B, or NGP5B, or control (BSA) (10 μg/dose/200 µL PBS, at
7-day intervals). Three weeks after the last immunization, the specific IgG levels were measured
by chemiluminescent ELISA, as previously described [112]. A strong antibody response was
observed in the animals immunized with NGP12B, NGP17B, or NGP5B when compared to the
control group (BSA) (Fig 3.3A). However, we also observed a significant cross-reactivity
between the NGPs, although antibodies against NGP5B had lower (~39-49%) cross-reactivity
with NGP12B and NGP17B. Next, to assess the protective ability of these NGPs, mice were
challenged with 1 x 105 L. major-luc metacyclic promastigotes and footpad lesion was evaluated
for 81 day post-challenge (Fig 3.3B). In comparison with control group (BSA), NGP5B
vaccination was able to maintain significantly lower lesion size in immunized mice throughout
the course of the infection. Although NGP12B and NGP17B showed a protective trend towards
the end of infection follow-up, there was no statistical significance when compared to BSA
group. Taken together, these results indicated that NGP5B had a higher protective effect than
NGP12B and NGP17B, and therefore was selected to be further evaluated as a vaccine
candidate.
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Fig 3.3 α-Gal-NGPs as potential vaccine candidates against L. major. (A) Chemiluminescent
ELISA to measure anti-α-Gal antibody levels in α1,3GalT-KO mice immunized with the α-Galcontaining NGP17B, NGP12B, or NGP5B. Immunizations groups are indicated in the legend,
whereas NGPs and control (BSA) used as antigens in the chemiluminescent ELISA are shown in
the Y-axis. Sera were used at 1:100 dilution. Two-way ANOVA with Tukey’s multiple
comparisons: ns, non-significant; (***), P<0.001; (****), P<0.0001. (B) Lesion size (mm) in
mice immunized with α-Gal-NGP (NGP12B, NGP17B, or NGP5B) or control (BSA), and then
challenged with 1 x 105 L. major-luc metacyclic promastigotes. One-way ANOVA (compared
with BSA control): ns, non-significant; (**), P<0.01. (A and B) Error bars indicate S.E.M. of
triplicate determinations.
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NGP5B elicits significant protection against L. major challenge in α1,3GalT-KO mice
First, six mice per group were immunized with NGP5B (10 μg/dose) or in combination with the
adjuvant CpG (20 μg/dose). Control mice groups were immunized with either 20 μg/dose of
CpG, or PBS. Prime (P) and 3 boost immunizations (B1-B3) were performed subcutaneously at
7-day intervals, followed by L. major challenge three weeks after last immunization (B3) (Fig
3.4A). In vivo bioluminescence imaging (n=3) was acquired at 14, 21, 33, and 43 day postinfection (dpi) (Fig 3.4B). Quantification of luminescence in the footpads is represented by the
radiance (photons per second per centimeter squared per steradian, p/s/cm2/sr) per infected
footpad/mouse. In comparison to the PBS control group, NGP5B significantly reduced
(P<0.0001) parasite bioluminescence, when administrated alone or in combination with the CpG
adjuvant(P<0.0001) (Fig 3.4C). This was corroborated by significant parasite load reduction in
the footpad as detected by qPCR in animals immunized with NGP5B (69%) (P<0.01) and
NGP5B+CpG (72%) (P<0.05), as compared to the PBS control group (Fig 3.4D). Furthermore,
in contrast to animals treated with CpG or PBS, animals vaccinated with NGP5B or, in
particular, NGP5B+CpG, gained weight following parasite challenge, indicating therefore that
these animals were healthy (Fig 3.4E). Taken together, these findings confirmed that both
NGP5B and NGP5B+CpG induce partial but significant protect against L. major infection.
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Fig 3.4 Vaccination with NGP5B or NGP5B+CpG elicits partial but significant protection
against L. major infection in α1,3GalT- KO mice. (A) Vaccination experimental design. Prime
(P), boost 1-3 (B1-B3). Three weeks after B3, immunized α1,3GalT-KO mice were challenge
with 1 x 105 L. major-luc metacyclic promastigotes. Experiment was concluded at 43 dpi. (B) In
vivo bioluminescence imaging of α1,3GalT-KO mice immunized with NGP5B, NGP5B+CpG,
CpG or PBS, and then challenged with 1 x 105 L. major-luc metacyclic promastigotes.
Bioluminescence images obtained at 14, 21, 33, and 43 dpi. (C) Quantification of
bioluminescence emitted in the footpad by α1,3GalT-KO mice immunized with NGP5B,
NGP5B+CpG, CpG, or PBS and challenged with L. major-luc metacyclic promastigotes. Twoway ANOVA with Dunnett’s multiple comparison test (compared with PBS group): (**), P
<0.01; (****), P<0.0001. (D) Quantification of parasitic load (parasites per footpad) by qPCR, at
the experimental endpoint (43 dpi). Two-way ANOVA with Dunnett’s multiple comparison test:
ns, non-significant; (*), P <0.05; (**), P<0.01. (E) Assessment of treatment toxicity established
by weight change in α1,3GalT-KO mice immunized with NGP5B, NGP5B+CpG, CpG, or PBS,
and then challenged. Two-way ANOVA with Dunnett’s multiple comparison test (compared
with PBS group): (*), P<0.05; (**), P<0.01. (C-E) Error bars indicate S.E.M. of triplicate
determinations.
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NGP5B induces a specific humoral immune response
To determine and characterize the humoral immune response produced by NGP5B and
NGP5B+CpG, sera from all groups were collected 3 days after each immunization (P and B1-3),
three weeks after last immunization, and at the endpoint (Fig 3.4A). First, the production of
specific anti-NGP5B IgG antibodies was analyzed by chemiluminescent ELISA using NGP5B as
antigen. As expected, high levels of specific IgG antibodies against NGP5B were observed in
mice immunized with NGP5B or NGP5B+CpG, when compared to PBS or CpG alone. The high
levels of anti-NGP5B antibodies were maintained until the experimental endpoint (Fig 3.5A).
Furthermore, murine immunoglobulin isotypes (IgG1, IgG2a, IgG2b, IgG3, and IgE) specific
against NGP5B were analyzed by ELISA (Fig 3.5B, C). At the end of the immunization (B3),
mice immunized with NGP5B+CpG showed the following rank of IgG subclasses:
IgG1>IgG2b>IgG2a>IgG3. Mice immunized with NGP5B alone, on the other hand, showed a
slightly different rank of IgG subclasses: IgG1>IgG3>IgG2a>IgG2b>IgE (Fig 3.5B). Moreover,
at the experimental endpoint (43 dpi), the levels of IgG1, IgG2a, IgG2b and IgG3 increased in
mice immunized with NGP5B+CpG. In contrast, in the NGP5B-immunized group we observed
an increase in IgG1, and decrease in IgG3 and IgG2a following L. major-luc challenge (Fig
3.5C). These results indicate that vaccination with NGP5B or NGP5B+CpG can stimulate

production of specific IgG isotypes. Furthermore, no increase in the levels of IgE was observed
following vaccination with NGP5B or NGP5B+CpG, or at the experimental endpoint (43 dpi).

Anti-NGP5B antibodies have lytic activity against L. major metacyclic promastigotes
The lytic activity of anti-NGP5B antibodies elicited by animals vaccinated with NGP5B or
NGP5B+CpG was investigated by incubating immunized mice sera with L. major-luc metacyclic
promastigotes. As observed in Fig 3.5D, NGP5B+CpG (P<0.001) and NGP5B (P<0.01) antisera
caused lysis in 60% and 44% of L. major-luc metacyclic promastigotes, respectively, when the
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complement was heat inactivated. Conversely, when complement in these antisera was active,
we observed no significant parasite lysis, indicating that somehow active complement interferes
with the parasite lysis. Therefore, mice immunized with NGP5B or NGP5B+CpG produced
antibodies that are lytic in a complement-independent manner, suggesting a mechanism similar
to lytic anti-α-Gal antibodies elicited against Trypanosoma cruzi trypomastigotes GPI-mucins
[106, 123].
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Fig 3.5 Analysis of humoral immune response of NGP5B immunized mice. (A)
Chemiluminescent ELISA reactivity against NGP5B of mouse sera obtained at prime (P), boost
1-3 (B1-B3), three weeks post-B3 (day 0) and at the endpoint (43 dpi) from α1,3GalT-KO mice
vaccinated with NGP5B, NGP5B+CpG, CpG, or PBS. (B-C) Antibody isotyping (IgG1, IgG2a,
IgG2b, IgG3, and IgE) of mouse sera obtained following boost 3 (B3) and at the experimental
endpoint (43 dpi). Statistical analysis for A-C: Two-way ANOVA with Dunnett’s multiple
comparison test: (*), P<0.05; (****), P<0.0001. (D) Percentage of lysis of L. major-luc
metacyclic promastigotes incubated with sera from mice immunized with NGP5B,
NGP5B+CpG, CpG or PBS. Control dead parasites: 106 L. major-luc metacyclic promastigotes,
heat-killed at 100oC for 10 min, followed by 30-min incubation at RT with PI. Control live
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comparisons (compared with NMS control): ns, non-significant; (**), P<0.01; (***), P<0.001.
(A-D) Error bars indicate S.E.M. of triplicate determinations.
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Anti-NGP5B response is specific against terminal α-Gal residues
The maleimide derivative succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(SMCC) cross-linker commonly used for the conjugation of carbohydrates and peptides to BSA
was reported to elicit high levels of anti-linker antibodies [124]. To detect antibodies against the
maleimide cross-linker used in our NGPs, maleimide-derivatized BSA (Fig 3.1A) was blocked
with 2-ME to give rise to 2ME-BSA [125]. The specificity of anti-NGP5B and anti-linker
antibodies of sera (3 weeks post-B3 and endpoint) from mice immunized with NGP5B,
NGP5B+CpG, CpG, or PBS was analyzed by chemiluminescent ELISA. As indicated in Fig
3.6A, sera from NGP5B- and NGP5B+CpG-immunized mice (3 weeks post-B3) had a very

strong and specific antibody reactivity (P<0.0001) against NGP5B antigen and a very weak
reactivity against the linker in 2ME-BSA antigen. However, we observed that at the endpoint of
the experiment (Fig 3.6B), contrary to NGP5B, NGP5B+CpG elicited a considerable antibody
response against 2ME-BSA. Next, NGP5B was treated or not with α-galactosidase, overnight at
37oC, to remove terminal α-Gal residues to confirm the main specificity of anti-NGP5B
antibodies. In comparison with untreated groups, we observed a significant (P<0.01) decrease in
the reactivity against NGP5B+CpG (90%) and NGP5B (75%) (Fig 3.6C). This result indicates
that most antibodies produced against NGP5B an NGP5B+CpG recognize the terminal α-Gal
residue in the NGP.
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determinations.
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NGP5B induces a protective Th1 cellular immune response
To study the cellular immune response induced by NGP5B and NGP5B+CpG vaccination in

α1,3GalT-KO mice, a panel of Th1, Th2, and Th17 cytokines (IL-12p40, IL-2, IFN-γ, TNF-α,
IL-5, IL-4, IL-10, IL-6, and IL-17) were analyzed in the sera of immunized mice before
challenge with L. major-luc three weeks after last immunization (day 0; Fig 4A). Significant
higher levels of Th1 cytokines: IL-12p40 (P<0.001), IL-2 (P<0.05), and IFN-γ (P<0.001) (Fig
3.7A-D); and Th2 cytokine IL-5 (P<0.05) (Fig 3.7G) were observed in NGP5B-immunized

group in comparison with control (naïve) group. Furthermore, we detected a significant increase
in the IFN-γ/IL-4 (P<0.05) and IFN-γ/IL-10 (P<0.05) ratios in mice vaccinated with NGP5B
(Fig 3.7H, I). A lower induction of proinflammatory cytokines was observed upon NGP5B+CpG
immunization. Only IL-12p40 (P<0.05) and TNF-α (P<0.05) were significantly increased in that
vaccinated group. On the other hand, we did not detect significant differences for IL-10, IL-4,
IL-17, and IL-6 regulatory cytokines in comparison with control group (Fig 3.7E, F, and data
not shown) in both NGP5B and NGP5B+CpG. In summary, these results suggest that animals

immunized with NGP5B showed strong protective Th1 cellular immune response against L.
major infection.
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Vaccination with NGP5B induces a robust T-cell response
We first assessed the antigen-specific response of CD4+ and CD8+ T cells, at three weeks after

last immunization (pre-challenge) and at the endpoint of the experiment (post-challenge). We
also evaluated the levels of activated CD69+ and memory CD44+ T cells in immunizedchallenged animals. NGP5B- and NGP5B+CpG-immunized mice developed a high expression of
antigen-specific CD4+ and CD8+ T cell response, with a significant increase in the post-challenge
time-points as compared to the control mice, CpG or PBS stimulated with NGP5B or
NGP5B+CpG antigen (Fig 3.8A-B). Interestingly, after mice were challenged with L. major, a
significant upregulation of memory CD44+CD4+ T cells and CD44+CD8+ T cells was found in
both NGP5B (P≤0.05) and NGP5B+CpG (P≤0.05) groups (Fig 3.8C, D), together with high
expression levels of CD4+CD69+ T cells (Fig 3.8C). These findings demonstrate that vaccination
with NGP5B and NGP5B+CpG in α1,3GalT-KO mice can induce a robust CD4+ T cell response,
accompanied by a CD8+ T cell response, both necessary for the protection against L. major.
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3.4

Discussion

Currently, leishmaniasis is endemic in 90 countries, with more than 2 million new cases
per year, and a worldwide incidence of 350 million people at risk of infection [93, 94]. CL is the
most common form of the disease with an estimated 0.7 to 1.2 million annual cases, representing
50-75% CL new cases [93]. Despite current advances [38, 126-129], there is no human vaccine
available that confers sterile protection against this neglected disease [130]. Nevertheless,
previous studies have shown that a vaccine against CL is a viable and feasible approach [131].
Thus, a preventive CL vaccine will have a great public health impact in terms of treatment and
preventing disease dissemination in conflict regions [94]. These facts underscore the urgent need
for the development of a fully protective vaccine against CL. Here, by targeting α-Gal
glycotopes abundantly expressed on the L. major surface [62, 63], we evaluated the first
synthetic α-Gal-containing NGP (Galα(1,6)Galβ-BSA or NGP5B) against L. major infection in
the α1,3GalT-KO mouse model.
First, we evaluated a series of eight synthetic α-Gal-containing NGPs as potential
biomarkers in serum samples from patients infected with L. major from Saudi Arabia. Three
highly differential biomarkers were selected (NGP17B, NGP12B, and NGP5B) and investigated
as potential vaccine candidates against L. major infection in a murine model. We observed high
levels of anti-α-Gal antibodies produced in α1,3GalT-KO mice vaccinated with NGP12B and
NGP17B, offering partial protection against L. major infection. More importantly, NGP5B
offered a significant, partial protection against the infection with a strong humoral response. To
increase the protection against L. major infection, the CpG-ODN adjuvant in combination with
NGP5B (NGP5B+CpG) was also evaluated. A robust antibody response was observed in both
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vaccinated groups (NGP5B and NGP5B+CpG), when compared to PBS and CpG control groups.
Previously, Yilmaz et al. (2014) studied a synthetic α-Gal epitope (Galα(1,3)Galβ(1,4)GlcNAc)
as vaccine candidate for Plasmodium infection [108]. Interestingly, they detected high levels of
IgG1, IgG2b, and IgG3, and little or no circulating IgG2a in immunized α1,3GalT-KO mice
[108]. Similarly, our NGP5B-immunized (noninfected) mice also showed high levels of IgG1
and IgG3, and lower levels of IgG2a and IgG2b subclasses. As for the NGP5B+CpG-immunized
noninfected group, high levels of IgG1, IgG2b, and IgG2a and low levels of IgG3 and IgE were
observed. The CpG adjuvant is known to increase murine B cells to produce IgG2a, IgG2b, and
IgG3 isotypes [132]. Taken together, these findings indicate that NGP5B+CpG, and to a slightly
lesser extent NGP5B, induces a strong IgG response associated with protection against L. major
infection.
Consequently, the study of lytic parasite-specific anti-α-Gal antibodies is also of great
interest in L. major infection as we anticipate that, similar to Chagas disease [103, 106, 110],
these antibodies could have a protect role against infection. Here, we observed that sera from
α1,3GalT-KO mice immunized NGP5B or NGP5B+CPG had a significant complementindependent lytic activity towards infective metacyclic promastigote forms of the parasite.
Brittingham et al. (1985) [133] have previously demonstrated that Leishmania is able to exploit
the opsonic effects of complement while avoiding complement-mediated lysis. The expression of
gp63 accelerates the change of C3b to its inactive form, reducing the fixation of terminal
complement components such as C5 and C7, and the formation of the membrane attack complex,
resulting in a resistance to complement-mediated lysis [133]. Furthermore, previous work in the
metacyclic promastigote form of the parasite demonstrate an increased resistance to
complement-mediated lysis in comparison to the promastigote form of the parasite [134]. Our
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study provides evidence that immunization with NGP5B or NGP5B+CPG can elicit anti-α-Gal
antibodies with lytic, complement-independent activity against L. major-luc metacyclic
promastigotes, which may serve as one of the mechanisms conferring protection against
infection.
To successfully control CL infection, a Th1-mediated immunity is desired [135, 136]. We
observed that NGP5B induced a predominantly Th1-mediated cellular immune response in
α1,3GalT-KO mice, with an increase in IL-12p40, IL-2, and IFN-γ, which are related to the
protection against CL. On the other hand, NGP5B+CpG induced mainly IL-12p40 and TNF-α.
Although not statistically significant, there was a trend of higher IL-12p40 level in the
NGP5B+CpG-immunized group in comparison to the group immunized with NGP5B alone. It
has been recently reported that CpG-ODN can upregulate the secretion of IL-12 by the help of
inflammatory monocytes [137]. It is known that macrophages are primarily involved in the
destruction of intracellular parasites such as L. major by the secretion of IL-12, causing the
differentiation of CD4+ T cells into Th1 cells and the production IFN-γ and IL-2 cytokines [138140]. The production of IL-12 and IFN-γ activates the up-regulation of nitric oxide in
macrophages producing an oxidative burst that subsequently kills the parasite. Additionally, no
significant increase in IL-10 and IL-4 cytokines were observed, which are associated with
disease progression through suppression of macrophage activation [138-140]. On the contrary,
significant higher IFN-γ/IL-4 and IFN-γ/IL-10 ratios, which are indicative of a favorable
outcome in CL infection [135], were observed in the animals vaccinated with NGP5B.
Interestingly, recruitment and maturation of eosinophils to the site of L. major infection is
modulated by the production of IL-5 and studies have shown that eosinophils play a role in
parasite clearance by suppressing the developing lesion and having antimicrobial activity against
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L. mexicana and L. donovani [141]. Therefore, induction of this cytokine, observed here by
immunization with NGP5B, could be beneficial for the control of L. major infection in
α1,3GalT-KO mice.
The activation and expansion of T cells are fundamental to mount an adaptive immune
response for long-term protection against L. major infection and essential in vaccine efficacy
optimization [142, 143]. Therefore, in our study, the cellular immune response was determined
by the percentage of activated CD4+ and CD8+ T cells in both immunized non-challenged, and
immunized challenged mice. Additionally, CD44 and CD69 expression was measured for T cell
activation before and after infection with L. major. First, we observed a robust antigen specific
CD4+ T cell response as well as a CD8+ T cell response before and after infection. Interestingly,
after infection (43 dpi), a high proportion of antigen specific CD4+ T cells expressing CD44 and
CD69 were observed in both NGP5B and NGP5B+CPG mice. Moreover, a small population of
CD8+ T cells expressing CD44 was also observed. This may suggest that antigen-dependent Tcell stimulation was still in course [144]. Altogether, these results suggest that NGP5B or
NGP5B+CPG vaccination can elicit strong T cell immunity, since both CD4+ and CD8+ T cells
are important in controlling parasite burden against L. major infection [135].
Previously, the immunogenicity of three different maleimide derivatives linkers was
investigated [124]. Interestingly, a high level of anti-linker antibodies was found against
maleimide-derivative linkers containing an additional aliphatic or aromatic ring [124]. In this
study, we found that NGP5B-vaccinated mice had a specific and strong antibody response
against the terminal α-Gal epitope in NGP5B, and not against the linker when using 2-ME-BSA
as antigen [125]. However, we observed that the NGP5B+CPG group had a significant antibody
response against 2-ME-BSA at the experimental endpoint (43 dpi), suggesting that the L. major
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infection might be eliciting antibodies that can cross-react with the linker. Nevertheless, for
future glycan conjugation to the carrier protein, a smaller and more flexible linker could be used
to achieve a more specific immune response against the glycotope [125].
Carbohydrates have been proposed as potential targets for vaccines against Leishmania
spp. [56, 57]. Vaccination with Leishmania lipophosphoglycan (LPG), one of the major
components of the glycocalyx of the parasite, revealed contradictory results [58, 59, 145]. For
instance, LPG purified from L. donovani failed to protect against L. major infection in BALB/c
mice [58]. Martinez Salazar et al. [146] suggested that L. mexicana LPG vaccination induced
upregulation of programmed cell death protein 1 (PD-1), leading to functional CD8+ T cell
inactivation and, consequently, disease progression. Conversely, Pinheiro et al. [59]
demonstrated that intranasal vaccination with L. amazonensis LPG provided protection in
BALB/c mice against subsequent parasite challenge. Additionally, a synthetic glycovaccine
containing fragments of the phosphoglycan moiety of LPG or proteophosphoglycan (PPG) from
L. mexicana exerted a protective effect in a natural sand fly infection model of CL caused L.
mexicana [60]. In the present study, we explored NGPs containing non-reducing, terminal α-Gal
epitopes similar to those found in Type-II GIPL-2 and GIPL-3 of L. major [62, 66], as preventive
CL vaccines. For instance, the NGP5B glycotope, Galα(1,6)Galβ, is analogous to the GIPL-3
glycotope, Galα(1,6)Galα-R, and showed to be highly reactive to sera from active CL infections
and partially protective in the α1,3GalT-KO mouse model. Evaluation of purified GIPL-3 or its
synthetic terminal α-Gal-containing glycotope(s) covalently coupled to a carrier protein as
vaccine candidates may provide evidence whether protective anti-α-Gal antibodies against
NGP5B cross-react with the native glycotope. Furthermore, we hypothesize that the α-Galterminating NGP5B, NGP12B, and NGP17B, evaluated here as vaccine candidates against L.
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major, and eventually additional α-Gal-terminating NGPs may protect against other Leishmania
species that express Type-II GIPLs (e.g., L. mexicana) [147] or Type-II-like GIPLs (e.g., L.
brasiliensis and L. infantum) [67]. We also speculate that similar or distinct α-Gal-terminating
glycotopes could be expressed in other Leishmania glycoconjugates (e.g., LPG and PPG) and
could play a protective role against leishmaniasis. In this regard, the evaluation of current and
additional α-Gal-terminating NGPs as vaccine candidates against other Leishmania species will
be pursued in future studies.
Previous reports have shown that the sand fly saliva plays a critical role in the
establishment and maintenance of Leishmania spp. in the mammalian host, as well as in the
pathogenesis of leishmaniasis and immune responses against the parasite (reviewed in [53, 54]).
Accordingly, the efficacy of vaccines against Leishmania spp. might be considerably influenced
by the parasite challenge procedure, either by needle or sand fly bite. For instance, Peters et al.
[148] showed that the protective effect of a complex L. major vaccine preparation in mice that
were initially needle-challenged could be subsequently abrogated by a sand fly-mediated
infection. On the other hand, Oliveira et al. [55] demonstrated that the protective effect of
Phlebotomus duboscqi uninfected sand fly bites in rhesus macaques. First, they observed that
only 30% of animals exposed to uninfected sand fly bites followed by vector-transmitted L.
major challenge, exhibited ulcerated lesions, in comparison to 70% of naïve animals.
Furthermore, macaques immunized with a P. duboscqi-derived recombinant salivary protein
(PdSP15), followed by sand fly-challenge with L. major, showed a significant reduction in
disease burden, resulting from an early Th1-mediated anti-parasitic protective immune response
involving CD4+IFN-γ+ T cells. Moreover, besides salivary proteins, Leishmania also releases
large quantities of promastigote secretory gel (PSG) within the sand fly, a glycoconjugate that is
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regurgitated along with parasites and is important for establishment of the infection in skin [149].
In summary, these and other studies (reviewed in [53, 54]) highlight the paramount importance
of the natural sand fly-transmitted model of infection in the assessment of efficacy of any
potential vaccine against Leishmania spp. To this end, the efficacy of current and novel α-Galterminating NGP vaccine candidates will eventually be evaluated in α1,3GalT-KO mice by sand
fly-mediated challenge.
In conclusion, here we have demonstrated that the α-Gal-terminating NGP5B vaccine
candidate, in the presence or not of CpG adjuvant, conferred partial but significant protection
against L. major infection in mice, by eliciting a robust B- and T-cell mediated immune response
through lytic, complement-independent anti-α-Gal antibodies and protective Th1 cytokines
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Chapter 4: Overview and final conclusions
The focus of the first part of this dissertation was to described the anti-leishmanicidal
effect of Ru-CTZ (AM160 or AM162) complexes in an in vivo model, and its potential
mechanism of action. The study of metal-based therapies against trypanosomatids was
previously investigated by the Sanchez-Delgado group [75]. They evaluated a first generation of
Ru-CTZ compounds, which showed higher activity towards T. cruzi than the parental drug CTZ,
and low cytotoxicity; however, poor solubility of the compounds lead them to synthetize a
second generation of Ru-CTZ complexes [75].
Previously, our group showed the significant in vitro activity of two second generation of
complex metal compounds known as AM160 and AM162 [1]. Both AM160 and AM162
increased the parasitic activity of CTZ on L. major promastigotes and amastigotes propagated
inside macrophages [1]. Nowadays, as a general rule for a successful drug candidate, in vivo
experiments are necessary. Therefore, we sought to study the therapeutic efficacy in vivo of the
Ru-CTZ compounds in the mouse model of CL. AM162 treatment with 4 mg/kg/day reduced the
lesion size by a 68%, a markedly better effect than CTZ alone or a RuII complex without CTZ. In
addition, AM162 significantly reduced the parasite burden in hyper infection experiments using
a dosage of 6 mg/kg/day. Therefore, these findings indicate that AM162 possess efficient antileishmaniasis activity in vivo, and that the combination of the metal and CTZ in a single
molecule is responsible for the anti-parasitic activity.
Furthermore, with the exception of amphotericin B, the mechanism of action of current
treatments against leishmaniasis are not completely understood. Thus, in the first part of this
dissertation, we also study the possible mechanism of cell death induced by AM160 or AM162
complex in L. major. Apoptosis has been reporter in anti-leishmanial drugs such as miltefosine
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and pentavalant antimonials, and it has been suggested as a favorable mechanism of cell death in
Leishmanias spp. [91]. To our satisfaction, AM160 and AM162 displayed pro-apoptotic-like
properties, encompassing hallmarks of apoptosis such as the externalization of phospholipids,
depolarization of the mitochondrial, and fragmentation of DNA.
Taken together, two metal-azole compounds displayed potent leishmanicidal in vitro
activity in L. major. However, since AM162 complex exhibited the best in vivo anti-L. major
activity. new delivery formulations of AM162 are important to be considered as a future
approach. In order to increase the compound solubility, delivery, and its anti-parasitic activity,
new formulations of AM162 are considered as a future direction.
It is understandable that vaccination is the best approach to control neglected infectious
diseases. Recently, carbohydrates have been proposed as potential targets for vaccines against
Leishmania spp. [56, 57]. In the second part of this dissertation, we explore NGPs containing
non-reducing, terminal α-Gal epitopes similar to those found in Type-II GIPL-2 and GIPL-3 of
L. major [62, 66], as preventive CL vaccines. Here, we evaluate the first synthetic α-Galcontaining NGP (Galα(1,6)Galβ-BSA or NGP5B) vaccine against L. major infection. First, the
immunogenicity and specificity of eight synthetic α-Gal-containing NGPs as potential
biomarkers in serum samples from patients infected with L. major from Saudi Arabia was
studied. Interestingly, three highly differential biomarkers were first selected (NGP17B,
NGP12B, and NGP5B), and further investigated as potential vaccine candidates against L. major
infection in an α1,3-galactosyltransferase-knockout (α1,3-GalT-KO). NGP5B significantly
decreased the footpad lesion, and parasite load of L. major infected α1,3-GalT-KO mice.
Furthermore, humoral and cellular immune response against NGP5B was evaluated. Our results
indicate that NGP5B elicits a strong humoral and cellular immune response by the production of
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high levels of specific α-Gal antibodies, pro-inflammatory Th1 cytokines, and activation of
memory and effector CD4+ and CD8+ T cells. These results clearly demonstrate the potential of
an α-Gal containing glycovaccine against leishmaniasis. However, further elucidation of the
mechanism of action and molecular targets of NGP5B may lead to a better understanding and
therefore improvement of NGP5B as a vaccine against CL.
Overall, the results from this dissertation provide novel insights and possibilities against
cutaneous leishmaniasis. The knowledge accumulated through these studies may eventually
result in the development of effective therapies against this parasite.
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